{"entity":"pfizer","name":"Pfizer","kind":"money","summary":"Pfizer's timeline holds 430 money & deals claims from 2006 to 2026. The latest took effect on October 28, 2026.","counts":{"total":439,"by_kind":{"people":1,"money":430,"products":0,"models":0,"other":8}},"events":[{"date":"2006-12-31","until":"2007-12-31","published":"2010-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 71,432,000,000 United States dollar\", as of 2006-12-31 (until 2007-12-31). Claim clm_A44E15832BBA, https://asof.is/claim/clm_A44E15832BBA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312510042425/0001193125-10-042425-index.htm.","url":"https://asof.is/claim/clm_A44E15832BBA","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"71,432,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A44E15832BBA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-K FY2009, filed 2010-02-26"}},{"date":"2006-12-31","until":"2007-12-31","published":"2010-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,827,000,000 United States dollar\", as of 2006-12-31 (until 2007-12-31). Claim clm_BF314FB38D8B, https://asof.is/claim/clm_BF314FB38D8B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312510042425/0001193125-10-042425-index.htm.","url":"https://asof.is/claim/clm_BF314FB38D8B","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,827,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BF314FB38D8B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2009, filed 2010-02-26"}},{"date":"2007-12-31","until":"2008-12-31","published":"2010-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer revenue: 48,418,000,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_495E00A572C1, https://asof.is/claim/clm_495E00A572C1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312510042425/0001193125-10-042425-index.htm.","url":"https://asof.is/claim/clm_495E00A572C1","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"48,418,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_495E00A572C1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2009, filed 2010-02-26"}},{"date":"2007-12-31","until":"2008-12-31","published":"2010-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 65,124,000,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_50C8E50BF4CE, https://asof.is/claim/clm_50C8E50BF4CE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312510042425/0001193125-10-042425-index.htm.","url":"https://asof.is/claim/clm_50C8E50BF4CE","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"65,124,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_50C8E50BF4CE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest in 10-K FY2009, filed 2010-02-26"}},{"date":"2007-12-31","until":"2008-06-29","published":"2010-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 3,406,000,000 United States dollar\", as of 2007-12-31 (until 2008-06-29). Claim clm_657E0C4F356B, https://asof.is/claim/clm_657E0C4F356B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312510042425/0001193125-10-042425-index.htm.","url":"https://asof.is/claim/clm_657E0C4F356B","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"3,406,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_657E0C4F356B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2009, filed 2010-02-26"}},{"date":"2007-12-31","until":"2008-12-31","published":"2010-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 8,144,000,000 United States dollar\", as of 2007-12-31 (until 2008-12-31). Claim clm_F74BB34F06D8, https://asof.is/claim/clm_F74BB34F06D8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312510042425/0001193125-10-042425-index.htm.","url":"https://asof.is/claim/clm_F74BB34F06D8","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"8,144,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F74BB34F06D8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2009, filed 2010-02-26"}},{"date":"2008-06-29","until":"2008-09-28","published":"2009-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,776,000,000 United States dollar\", as of 2008-06-29 (until 2008-09-28). Claim clm_823C3F05D7D5, https://asof.is/claim/clm_823C3F05D7D5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752309005774/0001157523-09-005774-index.htm.","url":"https://asof.is/claim/clm_823C3F05D7D5","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,776,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_823C3F05D7D5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2009, filed 2009-08-06"}},{"date":"2008-06-29","until":"2008-09-28","published":"2009-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 820,000,000 United States dollar\", as of 2008-06-29 (until 2008-09-28). Claim clm_977B68D613C1, https://asof.is/claim/clm_977B68D613C1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752309005774/0001157523-09-005774-index.htm.","url":"https://asof.is/claim/clm_977B68D613C1","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"820,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_977B68D613C1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2009, filed 2009-08-06"}},{"date":"2008-06-29","until":"2008-09-28","published":"2009-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 12,129,000,000 United States dollar\", as of 2008-06-29 (until 2008-09-28). Claim clm_99F313D7785B, https://asof.is/claim/clm_99F313D7785B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752309005774/0001157523-09-005774-index.htm.","url":"https://asof.is/claim/clm_99F313D7785B","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"12,129,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_99F313D7785B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2009, filed 2009-08-06"}},{"date":"2008-09-28","until":"2009-03-29","published":"2009-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 11,973,000,000 United States dollar\", as of 2008-09-28 (until 2009-03-29). Claim clm_2C0670CBF783, https://asof.is/claim/clm_2C0670CBF783, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752309007794/0001157523-09-007794-index.htm.","url":"https://asof.is/claim/clm_2C0670CBF783","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"11,973,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2C0670CBF783","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2009, filed 2009-11-05"}},{"date":"2008-09-28","until":"2009-03-29","published":"2009-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,278,000,000 United States dollar\", as of 2008-09-28 (until 2009-03-29). Claim clm_8E82440CB576, https://asof.is/claim/clm_8E82440CB576, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752309007794/0001157523-09-007794-index.htm.","url":"https://asof.is/claim/clm_8E82440CB576","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,278,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8E82440CB576","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2009, filed 2009-11-05"}},{"date":"2008-09-28","until":"2008-12-31","published":"2009-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,265,000,000 United States dollar\", as of 2008-09-28 (until 2008-12-31). Claim clm_B2FC24A2A4AC, https://asof.is/claim/clm_B2FC24A2A4AC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752309007794/0001157523-09-007794-index.htm.","url":"https://asof.is/claim/clm_B2FC24A2A4AC","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,265,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B2FC24A2A4AC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2009, filed 2009-11-05"}},{"date":"2008-12-31","until":"2009-06-28","published":"2010-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 57,556,000,000 United States dollar\", as of 2008-12-31 (until 2009-06-28). Claim clm_0EE19FD45775, https://asof.is/claim/clm_0EE19FD45775, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312510042425/0001193125-10-042425-index.htm.","url":"https://asof.is/claim/clm_0EE19FD45775","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"57,556,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0EE19FD45775","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2009, filed 2010-02-26"}},{"date":"2008-12-31","until":"2009-12-31","published":"2010-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer revenue: 48,296,000,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_1F836D2FE95A, https://asof.is/claim/clm_1F836D2FE95A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312510042425/0001193125-10-042425-index.htm.","url":"https://asof.is/claim/clm_1F836D2FE95A","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"48,296,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1F836D2FE95A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2009, filed 2010-02-26"}},{"date":"2008-12-31","until":"2009-03-29","published":"2010-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,122,000,000 United States dollar\", as of 2008-12-31 (until 2009-03-29). Claim clm_456937BD9935, https://asof.is/claim/clm_456937BD9935, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312510042425/0001193125-10-042425-index.htm.","url":"https://asof.is/claim/clm_456937BD9935","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,122,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_456937BD9935","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2009, filed 2010-02-26"}},{"date":"2008-12-31","until":"2009-06-28","published":"2010-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 111,148,000,000 United States dollar\", as of 2008-12-31 (until 2009-06-28). Claim clm_80F4EF63765D, https://asof.is/claim/clm_80F4EF63765D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312510042425/0001193125-10-042425-index.htm.","url":"https://asof.is/claim/clm_80F4EF63765D","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"111,148,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_80F4EF63765D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2009, filed 2010-02-26"}},{"date":"2008-12-31","until":"2009-12-31","published":"2010-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 8,104,000,000 United States dollar\", as of 2008-12-31 (until 2009-12-31). Claim clm_C2718C858D30, https://asof.is/claim/clm_C2718C858D30, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312510042425/0001193125-10-042425-index.htm.","url":"https://asof.is/claim/clm_C2718C858D30","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"8,104,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C2718C858D30","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2009, filed 2010-02-26"}},{"date":"2009-03-29","until":"2009-06-28","published":"2010-05-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,729,000,000 United States dollar\", as of 2009-03-29 (until 2009-06-28). Claim clm_2AA8DE019A2B, https://asof.is/claim/clm_2AA8DE019A2B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310003143/0001157523-10-003143-index.htm.","url":"https://asof.is/claim/clm_2AA8DE019A2B","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,729,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2AA8DE019A2B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2010, filed 2010-05-13"}},{"date":"2009-03-29","until":"2009-06-28","published":"2010-05-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,247,000,000 United States dollar\", as of 2009-03-29 (until 2009-06-28). Claim clm_7513C83BC1ED, https://asof.is/claim/clm_7513C83BC1ED, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310003143/0001157523-10-003143-index.htm.","url":"https://asof.is/claim/clm_7513C83BC1ED","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,247,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7513C83BC1ED","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2010, filed 2010-05-13"}},{"date":"2009-03-29","until":"2009-06-28","published":"2010-05-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 10,867,000,000 United States dollar\", as of 2009-03-29 (until 2009-06-28). Claim clm_94472D618440, https://asof.is/claim/clm_94472D618440, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310003143/0001157523-10-003143-index.htm.","url":"https://asof.is/claim/clm_94472D618440","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"10,867,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_94472D618440","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2010, filed 2010-05-13"}},{"date":"2009-06-28","until":"2009-09-27","published":"2009-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 10,984,000,000 United States dollar\", as of 2009-06-28 (until 2009-09-27). Claim clm_879A3913E571, https://asof.is/claim/clm_879A3913E571, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752309005774/0001157523-09-005774-index.htm.","url":"https://asof.is/claim/clm_879A3913E571","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"10,984,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_879A3913E571","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2009, filed 2009-08-06"}},{"date":"2009-06-28","until":"2009-09-27","published":"2009-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 139,339,000,000 United States dollar\", as of 2009-06-28 (until 2009-09-27). Claim clm_B757021A10F9, https://asof.is/claim/clm_B757021A10F9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752309005774/0001157523-09-005774-index.htm.","url":"https://asof.is/claim/clm_B757021A10F9","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"139,339,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B757021A10F9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2009, filed 2009-08-06"}},{"date":"2009-06-28","until":"2009-09-27","published":"2009-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 63,041,000,000 United States dollar\", as of 2009-06-28 (until 2009-09-27). Claim clm_C31091B4FC83, https://asof.is/claim/clm_C31091B4FC83, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752309005774/0001157523-09-005774-index.htm.","url":"https://asof.is/claim/clm_C31091B4FC83","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"63,041,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C31091B4FC83","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2009, filed 2009-08-06"}},{"date":"2009-06-28","until":"2009-09-27","published":"2009-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,244,000,000 United States dollar\", as of 2009-06-28 (until 2009-09-27). Claim clm_DC6FEECF696C, https://asof.is/claim/clm_DC6FEECF696C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752309005774/0001157523-09-005774-index.htm.","url":"https://asof.is/claim/clm_DC6FEECF696C","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,244,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DC6FEECF696C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2009, filed 2009-08-06"}},{"date":"2009-06-28","until":"2009-09-27","published":"2009-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,261,000,000 United States dollar\", as of 2009-06-28 (until 2009-09-27). Claim clm_F30A5FDED738, https://asof.is/claim/clm_F30A5FDED738, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752309005774/0001157523-09-005774-index.htm.","url":"https://asof.is/claim/clm_F30A5FDED738","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,261,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F30A5FDED738","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2009, filed 2009-08-06"}},{"date":"2009-08-04","until":"2009-11-02","published":"2009-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 6,749,143,013 shares\", as of 2009-08-04 (until 2009-11-02). Claim clm_2668779849C3, https://asof.is/claim/clm_2668779849C3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752309005774/0001157523-09-005774-index.htm.","url":"https://asof.is/claim/clm_2668779849C3","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"6,749,143,013 shares","status":"superseded","assertable":true,"id":"clm_2668779849C3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2009, filed 2009-08-06"}},{"date":"2009-09-27","until":"2010-04-04","published":"2009-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 11,621,000,000 United States dollar\", as of 2009-09-27 (until 2010-04-04). Claim clm_53DFF240A651, https://asof.is/claim/clm_53DFF240A651, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752309007794/0001157523-09-007794-index.htm.","url":"https://asof.is/claim/clm_53DFF240A651","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"11,621,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_53DFF240A651","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2009, filed 2009-11-05"}},{"date":"2009-09-27","until":"2009-12-31","published":"2011-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 4,234,000,000 United States dollar\", as of 2009-09-27 (until 2009-12-31). Claim clm_5CD35DE98927, https://asof.is/claim/clm_5CD35DE98927, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312511048877/0001193125-11-048877-index.htm.","url":"https://asof.is/claim/clm_5CD35DE98927","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"4,234,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5CD35DE98927","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2010, filed 2011-02-28"}},{"date":"2009-09-27","until":"2009-12-31","published":"2009-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 66,157,000,000 United States dollar\", as of 2009-09-27 (until 2009-12-31). Claim clm_A3466E9F3750, https://asof.is/claim/clm_A3466E9F3750, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752309007794/0001157523-09-007794-index.htm.","url":"https://asof.is/claim/clm_A3466E9F3750","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"66,157,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A3466E9F3750","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2009, filed 2009-11-05"}},{"date":"2009-09-27","until":"2010-04-04","published":"2009-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,878,000,000 United States dollar\", as of 2009-09-27 (until 2010-04-04). Claim clm_C34AE65C49EF, https://asof.is/claim/clm_C34AE65C49EF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752309007794/0001157523-09-007794-index.htm.","url":"https://asof.is/claim/clm_C34AE65C49EF","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,878,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C34AE65C49EF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2009, filed 2009-11-05"}},{"date":"2009-09-27","until":"2009-12-31","published":"2009-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 141,294,000,000 United States dollar\", as of 2009-09-27 (until 2009-12-31). Claim clm_F1B30DB044E1, https://asof.is/claim/clm_F1B30DB044E1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752309007794/0001157523-09-007794-index.htm.","url":"https://asof.is/claim/clm_F1B30DB044E1","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"141,294,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F1B30DB044E1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2009, filed 2009-11-05"}},{"date":"2009-11-02","until":"2010-02-18","published":"2009-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 8,069,536,059 shares\", as of 2009-11-02 (until 2010-02-18). Claim clm_2F61DDCCEF64, https://asof.is/claim/clm_2F61DDCCEF64, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752309007794/0001157523-09-007794-index.htm.","url":"https://asof.is/claim/clm_2F61DDCCEF64","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"8,069,536,059 shares","status":"superseded","assertable":true,"id":"clm_2F61DDCCEF64","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2009, filed 2009-11-05"}},{"date":"2009-12-31","until":"2010-04-04","published":"2010-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 212,949,000,000 United States dollar\", as of 2009-12-31 (until 2010-04-04). Claim clm_13EB16805D7C, https://asof.is/claim/clm_13EB16805D7C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312510042425/0001193125-10-042425-index.htm.","url":"https://asof.is/claim/clm_13EB16805D7C","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"212,949,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_13EB16805D7C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2009, filed 2010-02-26"}},{"date":"2009-12-31","until":"2010-04-04","published":"2010-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 90,014,000,000 United States dollar\", as of 2009-12-31 (until 2010-04-04). Claim clm_9954D20E0A5E, https://asof.is/claim/clm_9954D20E0A5E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312510042425/0001193125-10-042425-index.htm.","url":"https://asof.is/claim/clm_9954D20E0A5E","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"90,014,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9954D20E0A5E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2009, filed 2010-02-26"}},{"date":"2009-12-31","until":"2010-12-31","published":"2010-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer revenue: 50,009,000,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_A65C4083AE17, https://asof.is/claim/clm_A65C4083AE17, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312510042425/0001193125-10-042425-index.htm.","url":"https://asof.is/claim/clm_A65C4083AE17","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"50,009,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A65C4083AE17","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2009, filed 2010-02-26"}},{"date":"2009-12-31","until":"2010-12-31","published":"2010-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 8,635,000,000 United States dollar\", as of 2009-12-31 (until 2010-12-31). Claim clm_D31D477BB1ED, https://asof.is/claim/clm_D31D477BB1ED, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312510042425/0001193125-10-042425-index.htm.","url":"https://asof.is/claim/clm_D31D477BB1ED","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"8,635,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D31D477BB1ED","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2009, filed 2010-02-26"}},{"date":"2010-01-04","until":"2010-04-04","published":"2010-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,978,000,000 United States dollar\", as of 2010-01-04 (until 2010-04-04). Claim clm_2E5E4898B1C3, https://asof.is/claim/clm_2E5E4898B1C3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752311004964/0001157523-11-004964-index.htm.","url":"https://asof.is/claim/clm_2E5E4898B1C3","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,978,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2E5E4898B1C3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2011, filed 2011-08-11"}},{"date":"2010-02-18","until":"2010-05-10","published":"2010-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 8,070,372,772 shares\", as of 2010-02-18 (until 2010-05-10). Claim clm_515548A675B9, https://asof.is/claim/clm_515548A675B9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312510042425/0001193125-10-042425-index.htm.","url":"https://asof.is/claim/clm_515548A675B9","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"8,070,372,772 shares","status":"superseded","assertable":true,"id":"clm_515548A675B9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2009, filed 2010-02-26"}},{"date":"2010-04-04","until":"2010-07-04","published":"2010-05-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,759,000,000 United States dollar\", as of 2010-04-04 (until 2010-07-04). Claim clm_398773C0161F, https://asof.is/claim/clm_398773C0161F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310003143/0001157523-10-003143-index.htm.","url":"https://asof.is/claim/clm_398773C0161F","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,759,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_398773C0161F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2010, filed 2010-05-13"}},{"date":"2010-04-04","until":"2010-07-04","published":"2010-05-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 89,659,000,000 United States dollar\", as of 2010-04-04 (until 2010-07-04). Claim clm_6A6B80D0E7A6, https://asof.is/claim/clm_6A6B80D0E7A6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310003143/0001157523-10-003143-index.htm.","url":"https://asof.is/claim/clm_6A6B80D0E7A6","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"89,659,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6A6B80D0E7A6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2010, filed 2010-05-13"}},{"date":"2010-04-04","until":"2010-07-04","published":"2010-05-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 16,750,000,000 United States dollar\", as of 2010-04-04 (until 2010-07-04). Claim clm_AD86DB08CC3F, https://asof.is/claim/clm_AD86DB08CC3F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310003143/0001157523-10-003143-index.htm.","url":"https://asof.is/claim/clm_AD86DB08CC3F","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"16,750,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AD86DB08CC3F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2010, filed 2010-05-13"}},{"date":"2010-04-04","until":"2010-07-04","published":"2010-05-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 195,113,000,000 United States dollar\", as of 2010-04-04 (until 2010-07-04). Claim clm_C43ED5B8E7AD, https://asof.is/claim/clm_C43ED5B8E7AD, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310003143/0001157523-10-003143-index.htm.","url":"https://asof.is/claim/clm_C43ED5B8E7AD","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"195,113,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C43ED5B8E7AD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2010, filed 2010-05-13"}},{"date":"2010-04-04","until":"2010-07-04","published":"2010-05-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,026,000,000 United States dollar\", as of 2010-04-04 (until 2010-07-04). Claim clm_F0B5626F99F2, https://asof.is/claim/clm_F0B5626F99F2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310003143/0001157523-10-003143-index.htm.","url":"https://asof.is/claim/clm_F0B5626F99F2","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,026,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F0B5626F99F2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2010, filed 2010-05-13"}},{"date":"2010-05-10","until":"2010-08-09","published":"2010-05-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 8,066,133,809 shares\", as of 2010-05-10 (until 2010-08-09). Claim clm_357A717950D2, https://asof.is/claim/clm_357A717950D2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310003143/0001157523-10-003143-index.htm.","url":"https://asof.is/claim/clm_357A717950D2","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"8,066,133,809 shares","status":"superseded","assertable":true,"id":"clm_357A717950D2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2010, filed 2010-05-13"}},{"date":"2010-07-04","until":"2010-10-03","published":"2010-08-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,877,000,000 United States dollar\", as of 2010-07-04 (until 2010-10-03). Claim clm_018D4EFE9889, https://asof.is/claim/clm_018D4EFE9889, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310005034/0001157523-10-005034-index.htm.","url":"https://asof.is/claim/clm_018D4EFE9889","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,877,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_018D4EFE9889","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2010, filed 2010-08-12"}},{"date":"2010-07-04","until":"2010-10-03","published":"2010-08-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 17,327,000,000 United States dollar\", as of 2010-07-04 (until 2010-10-03). Claim clm_8978D5AA8E4F, https://asof.is/claim/clm_8978D5AA8E4F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310005034/0001157523-10-005034-index.htm.","url":"https://asof.is/claim/clm_8978D5AA8E4F","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"17,327,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8978D5AA8E4F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2010, filed 2010-08-12"}},{"date":"2010-07-04","until":"2010-10-03","published":"2010-08-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,475,000,000 United States dollar\", as of 2010-07-04 (until 2010-10-03). Claim clm_DB84580754B2, https://asof.is/claim/clm_DB84580754B2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310005034/0001157523-10-005034-index.htm.","url":"https://asof.is/claim/clm_DB84580754B2","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,475,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DB84580754B2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2010, filed 2010-08-12"}},{"date":"2010-07-04","until":"2010-10-03","published":"2010-08-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 86,439,000,000 United States dollar\", as of 2010-07-04 (until 2010-10-03). Claim clm_DBE3ABE68677, https://asof.is/claim/clm_DBE3ABE68677, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310005034/0001157523-10-005034-index.htm.","url":"https://asof.is/claim/clm_DBE3ABE68677","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"86,439,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DBE3ABE68677","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2010, filed 2010-08-12"}},{"date":"2010-07-04","until":"2010-10-03","published":"2010-08-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 191,071,000,000 United States dollar\", as of 2010-07-04 (until 2010-10-03). Claim clm_E306A05D90FF, https://asof.is/claim/clm_E306A05D90FF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310005034/0001157523-10-005034-index.htm.","url":"https://asof.is/claim/clm_E306A05D90FF","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"191,071,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E306A05D90FF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2010, filed 2010-08-12"}},{"date":"2010-08-09","until":"2010-11-08","published":"2010-08-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 8,038,278,387 shares\", as of 2010-08-09 (until 2010-11-08). Claim clm_D35870DD68E8, https://asof.is/claim/clm_D35870DD68E8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310005034/0001157523-10-005034-index.htm.","url":"https://asof.is/claim/clm_D35870DD68E8","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"8,038,278,387 shares","status":"superseded","assertable":true,"id":"clm_D35870DD68E8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2010, filed 2010-08-12"}},{"date":"2010-10-03","until":"2011-04-03","published":"2010-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 866,000,000 United States dollar\", as of 2010-10-03 (until 2011-04-03). Claim clm_5B10E30EA2A3, https://asof.is/claim/clm_5B10E30EA2A3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310006832/0001157523-10-006832-index.htm.","url":"https://asof.is/claim/clm_5B10E30EA2A3","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"866,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5B10E30EA2A3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2010, filed 2010-11-12"}},{"date":"2010-10-03","until":"2010-12-31","published":"2010-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 87,635,000,000 United States dollar\", as of 2010-10-03 (until 2010-12-31). Claim clm_5E3BEFFD2F54, https://asof.is/claim/clm_5E3BEFFD2F54, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310006832/0001157523-10-006832-index.htm.","url":"https://asof.is/claim/clm_5E3BEFFD2F54","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"87,635,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5E3BEFFD2F54","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2010, filed 2010-11-12"}},{"date":"2010-10-03","until":"2011-04-03","published":"2010-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 16,171,000,000 United States dollar\", as of 2010-10-03 (until 2011-04-03). Claim clm_ADF1E4CD8AB3, https://asof.is/claim/clm_ADF1E4CD8AB3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310006832/0001157523-10-006832-index.htm.","url":"https://asof.is/claim/clm_ADF1E4CD8AB3","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"16,171,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ADF1E4CD8AB3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2010, filed 2010-11-12"}},{"date":"2010-10-03","until":"2010-12-31","published":"2010-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,176,000,000 United States dollar\", as of 2010-10-03 (until 2010-12-31). Claim clm_B37D5E701CBB, https://asof.is/claim/clm_B37D5E701CBB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310006832/0001157523-10-006832-index.htm.","url":"https://asof.is/claim/clm_B37D5E701CBB","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,176,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B37D5E701CBB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2010, filed 2010-11-12"}},{"date":"2010-10-03","until":"2010-12-31","published":"2010-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 191,415,000,000 United States dollar\", as of 2010-10-03 (until 2010-12-31). Claim clm_C41CA6BF091F, https://asof.is/claim/clm_C41CA6BF091F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310006832/0001157523-10-006832-index.htm.","url":"https://asof.is/claim/clm_C41CA6BF091F","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"191,415,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C41CA6BF091F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2010, filed 2010-11-12"}},{"date":"2010-11-08","until":"2011-02-22","published":"2010-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 8,009,951,287 shares\", as of 2010-11-08 (until 2011-02-22). Claim clm_EA397F991143, https://asof.is/claim/clm_EA397F991143, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752310006832/0001157523-10-006832-index.htm.","url":"https://asof.is/claim/clm_EA397F991143","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"8,009,951,287 shares","status":"superseded","assertable":true,"id":"clm_EA397F991143","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2010, filed 2010-11-12"}},{"date":"2010-12-31","until":"2011-04-03","published":"2011-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,735,000,000 United States dollar\", as of 2010-12-31 (until 2011-04-03). Claim clm_6C497B38FE04, https://asof.is/claim/clm_6C497B38FE04, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312511048877/0001193125-11-048877-index.htm.","url":"https://asof.is/claim/clm_6C497B38FE04","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,735,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6C497B38FE04","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2010, filed 2011-02-28"}},{"date":"2010-12-31","until":"2011-04-03","published":"2011-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 87,813,000,000 United States dollar\", as of 2010-12-31 (until 2011-04-03). Claim clm_A549A2DCF716, https://asof.is/claim/clm_A549A2DCF716, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312511048877/0001193125-11-048877-index.htm.","url":"https://asof.is/claim/clm_A549A2DCF716","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"87,813,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A549A2DCF716","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2010, filed 2011-02-28"}},{"date":"2010-12-31","until":"2011-04-03","published":"2011-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 195,014,000,000 United States dollar\", as of 2010-12-31 (until 2011-04-03). Claim clm_B5EF2CC1CA97, https://asof.is/claim/clm_B5EF2CC1CA97, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312511048877/0001193125-11-048877-index.htm.","url":"https://asof.is/claim/clm_B5EF2CC1CA97","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"195,014,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B5EF2CC1CA97","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2010, filed 2011-02-28"}},{"date":"2010-12-31","until":"2011-12-31","published":"2011-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer revenue: 67,809,000,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_F12BB6E4F260, https://asof.is/claim/clm_F12BB6E4F260, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312511048877/0001193125-11-048877-index.htm.","url":"https://asof.is/claim/clm_F12BB6E4F260","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"67,809,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F12BB6E4F260","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2010, filed 2011-02-28"}},{"date":"2010-12-31","until":"2011-12-31","published":"2011-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 8,257,000,000 United States dollar\", as of 2010-12-31 (until 2011-12-31). Claim clm_F86870CAEBB2, https://asof.is/claim/clm_F86870CAEBB2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312511048877/0001193125-11-048877-index.htm.","url":"https://asof.is/claim/clm_F86870CAEBB2","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"8,257,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F86870CAEBB2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2010, filed 2011-02-28"}},{"date":"2011-02-22","until":"2011-05-09","published":"2011-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 7,995,220,402 shares\", as of 2011-02-22 (until 2011-05-09). Claim clm_535B859BCCA4, https://asof.is/claim/clm_535B859BCCA4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312511048877/0001193125-11-048877-index.htm.","url":"https://asof.is/claim/clm_535B859BCCA4","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"7,995,220,402 shares","status":"superseded","assertable":true,"id":"clm_535B859BCCA4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2010, filed 2011-02-28"}},{"date":"2011-04-03","until":"2011-07-03","published":"2011-05-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,222,000,000 United States dollar\", as of 2011-04-03 (until 2011-07-03). Claim clm_12C33818541B, https://asof.is/claim/clm_12C33818541B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752311003088/0001157523-11-003088-index.htm.","url":"https://asof.is/claim/clm_12C33818541B","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,222,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_12C33818541B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2011, filed 2011-05-12"}},{"date":"2011-04-03","until":"2011-07-03","published":"2011-05-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 90,067,000,000 United States dollar\", as of 2011-04-03 (until 2011-07-03). Claim clm_2DFA220BB1CB, https://asof.is/claim/clm_2DFA220BB1CB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752311003088/0001157523-11-003088-index.htm.","url":"https://asof.is/claim/clm_2DFA220BB1CB","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"90,067,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2DFA220BB1CB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2011, filed 2011-05-12"}},{"date":"2011-04-03","until":"2011-07-03","published":"2011-05-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 16,502,000,000 United States dollar\", as of 2011-04-03 (until 2011-07-03). Claim clm_483D9F5A030A, https://asof.is/claim/clm_483D9F5A030A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752311003088/0001157523-11-003088-index.htm.","url":"https://asof.is/claim/clm_483D9F5A030A","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"16,502,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_483D9F5A030A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2011, filed 2011-05-12"}},{"date":"2011-04-03","until":"2011-07-03","published":"2011-05-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 730,000,000 United States dollar\", as of 2011-04-03 (until 2011-07-03). Claim clm_5FAC999C4B16, https://asof.is/claim/clm_5FAC999C4B16, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752311003088/0001157523-11-003088-index.htm.","url":"https://asof.is/claim/clm_5FAC999C4B16","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"730,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5FAC999C4B16","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2011, filed 2011-05-12"}},{"date":"2011-04-03","until":"2011-07-03","published":"2011-05-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 194,956,000,000 United States dollar\", as of 2011-04-03 (until 2011-07-03). Claim clm_C923C253734B, https://asof.is/claim/clm_C923C253734B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752311003088/0001157523-11-003088-index.htm.","url":"https://asof.is/claim/clm_C923C253734B","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"194,956,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C923C253734B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2011, filed 2011-05-12"}},{"date":"2011-05-09","until":"2011-08-08","published":"2011-05-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 7,901,130,426 shares\", as of 2011-05-09 (until 2011-08-08). Claim clm_BF85E394C5EA, https://asof.is/claim/clm_BF85E394C5EA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752311003088/0001157523-11-003088-index.htm.","url":"https://asof.is/claim/clm_BF85E394C5EA","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"7,901,130,426 shares","status":"superseded","assertable":true,"id":"clm_BF85E394C5EA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2011, filed 2011-05-12"}},{"date":"2011-07-03","until":"2011-10-02","published":"2011-08-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,610,000,000 United States dollar\", as of 2011-07-03 (until 2011-10-02). Claim clm_16050C72E7A4, https://asof.is/claim/clm_16050C72E7A4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752311004964/0001157523-11-004964-index.htm.","url":"https://asof.is/claim/clm_16050C72E7A4","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,610,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_16050C72E7A4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2011, filed 2011-08-11"}},{"date":"2011-07-03","until":"2011-10-02","published":"2011-08-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 88,481,000,000 United States dollar\", as of 2011-07-03 (until 2011-10-02). Claim clm_91AEC22309BC, https://asof.is/claim/clm_91AEC22309BC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752311004964/0001157523-11-004964-index.htm.","url":"https://asof.is/claim/clm_91AEC22309BC","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"88,481,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_91AEC22309BC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2011, filed 2011-08-11"}},{"date":"2011-07-03","until":"2011-10-02","published":"2011-08-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 16,984,000,000 United States dollar\", as of 2011-07-03 (until 2011-10-02). Claim clm_A68C0CCB75B0, https://asof.is/claim/clm_A68C0CCB75B0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752311004964/0001157523-11-004964-index.htm.","url":"https://asof.is/claim/clm_A68C0CCB75B0","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"16,984,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A68C0CCB75B0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2011, filed 2011-08-11"}},{"date":"2011-07-03","until":"2011-10-02","published":"2011-08-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 3,096,000,000 United States dollar\", as of 2011-07-03 (until 2011-10-02). Claim clm_E86C2405CE54, https://asof.is/claim/clm_E86C2405CE54, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752311004964/0001157523-11-004964-index.htm.","url":"https://asof.is/claim/clm_E86C2405CE54","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"3,096,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E86C2405CE54","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2011, filed 2011-08-11"}},{"date":"2011-07-03","until":"2011-10-02","published":"2011-08-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 195,899,000,000 United States dollar\", as of 2011-07-03 (until 2011-10-02). Claim clm_F165936EC27C, https://asof.is/claim/clm_F165936EC27C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752311004964/0001157523-11-004964-index.htm.","url":"https://asof.is/claim/clm_F165936EC27C","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"195,899,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F165936EC27C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2011, filed 2011-08-11"}},{"date":"2011-08-08","until":"2011-11-07","published":"2011-08-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 7,802,126,616 shares\", as of 2011-08-08 (until 2011-11-07). Claim clm_04A1C26B691D, https://asof.is/claim/clm_04A1C26B691D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752311004964/0001157523-11-004964-index.htm.","url":"https://asof.is/claim/clm_04A1C26B691D","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"7,802,126,616 shares","status":"superseded","assertable":true,"id":"clm_04A1C26B691D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2011, filed 2011-08-11"}},{"date":"2011-10-02","until":"2011-12-31","published":"2011-11-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 196,132,000,000 United States dollar\", as of 2011-10-02 (until 2011-12-31). Claim clm_4FB2D51234DD, https://asof.is/claim/clm_4FB2D51234DD, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752311006714/0001157523-11-006714-index.htm.","url":"https://asof.is/claim/clm_4FB2D51234DD","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"196,132,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4FB2D51234DD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2011, filed 2011-11-10"}},{"date":"2011-10-02","until":"2012-04-01","published":"2011-11-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 3,738,000,000 United States dollar\", as of 2011-10-02 (until 2012-04-01). Claim clm_7954AC74C4CF, https://asof.is/claim/clm_7954AC74C4CF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752311006714/0001157523-11-006714-index.htm.","url":"https://asof.is/claim/clm_7954AC74C4CF","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"3,738,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7954AC74C4CF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2011, filed 2011-11-10"}},{"date":"2011-10-02","until":"2011-12-31","published":"2011-11-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 90,047,000,000 United States dollar\", as of 2011-10-02 (until 2011-12-31). Claim clm_81A4E77710C7, https://asof.is/claim/clm_81A4E77710C7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752311006714/0001157523-11-006714-index.htm.","url":"https://asof.is/claim/clm_81A4E77710C7","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"90,047,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_81A4E77710C7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2011, filed 2011-11-10"}},{"date":"2011-10-02","until":"2011-12-31","published":"2011-11-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 3,706,000,000 United States dollar\", as of 2011-10-02 (until 2011-12-31). Claim clm_DC415530A071, https://asof.is/claim/clm_DC415530A071, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752311006714/0001157523-11-006714-index.htm.","url":"https://asof.is/claim/clm_DC415530A071","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"3,706,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DC415530A071","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2011, filed 2011-11-10"}},{"date":"2011-10-02","until":"2012-04-01","published":"2011-11-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 17,193,000,000 United States dollar\", as of 2011-10-02 (until 2012-04-01). Claim clm_DFEA39DE5FE8, https://asof.is/claim/clm_DFEA39DE5FE8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752311006714/0001157523-11-006714-index.htm.","url":"https://asof.is/claim/clm_DFEA39DE5FE8","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"17,193,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DFEA39DE5FE8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2011, filed 2011-11-10"}},{"date":"2011-11-07","until":"2012-02-21","published":"2011-11-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 7,686,966,786 shares\", as of 2011-11-07 (until 2012-02-21). Claim clm_5BF54CE43802, https://asof.is/claim/clm_5BF54CE43802, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752311006714/0001157523-11-006714-index.htm.","url":"https://asof.is/claim/clm_5BF54CE43802","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"7,686,966,786 shares","status":"superseded","assertable":true,"id":"clm_5BF54CE43802","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2011, filed 2011-11-10"}},{"date":"2011-12-31","until":"2012-12-31","published":"2012-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 10,009,000,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_18F8E59667BA, https://asof.is/claim/clm_18F8E59667BA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312512085703/0001193125-12-085703-index.htm.","url":"https://asof.is/claim/clm_18F8E59667BA","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"10,009,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_18F8E59667BA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2011, filed 2012-02-28"}},{"date":"2011-12-31","until":"2012-04-01","published":"2012-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 3,539,000,000 United States dollar\", as of 2011-12-31 (until 2012-04-01). Claim clm_1D79692E363C, https://asof.is/claim/clm_1D79692E363C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312512085703/0001193125-12-085703-index.htm.","url":"https://asof.is/claim/clm_1D79692E363C","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"3,539,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1D79692E363C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2011, filed 2012-02-28"}},{"date":"2011-12-31","until":"2012-04-01","published":"2012-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 188,002,000,000 United States dollar\", as of 2011-12-31 (until 2012-04-01). Claim clm_20A2C1DEA710, https://asof.is/claim/clm_20A2C1DEA710, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312512085703/0001193125-12-085703-index.htm.","url":"https://asof.is/claim/clm_20A2C1DEA710","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"188,002,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_20A2C1DEA710","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2011, filed 2012-02-28"}},{"date":"2011-12-31","until":"2012-12-31","published":"2012-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer revenue: 67,425,000,000 United States dollar\", as of 2011-12-31 (until 2012-12-31). Claim clm_4853ED0711DB, https://asof.is/claim/clm_4853ED0711DB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312512085703/0001193125-12-085703-index.htm.","url":"https://asof.is/claim/clm_4853ED0711DB","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"67,425,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4853ED0711DB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2011, filed 2012-02-28"}},{"date":"2011-12-31","until":"2012-04-01","published":"2012-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 82,190,000,000 United States dollar\", as of 2011-12-31 (until 2012-04-01). Claim clm_6FD4760A214C, https://asof.is/claim/clm_6FD4760A214C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312512085703/0001193125-12-085703-index.htm.","url":"https://asof.is/claim/clm_6FD4760A214C","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"82,190,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6FD4760A214C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2011, filed 2012-02-28"}},{"date":"2012-02-21","until":"2012-05-07","published":"2012-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 7,538,520,276 shares\", as of 2012-02-21 (until 2012-05-07). Claim clm_592610A1C932, https://asof.is/claim/clm_592610A1C932, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000119312512085703/0001193125-12-085703-index.htm.","url":"https://asof.is/claim/clm_592610A1C932","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"7,538,520,276 shares","status":"superseded","assertable":true,"id":"clm_592610A1C932","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2011, filed 2012-02-28"}},{"date":"2012-04-01","until":"2012-07-01","published":"2012-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,934,000,000 United States dollar\", as of 2012-04-01 (until 2012-07-01). Claim clm_2707D6258CA2, https://asof.is/claim/clm_2707D6258CA2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752312002789/0001157523-12-002789-index.htm.","url":"https://asof.is/claim/clm_2707D6258CA2","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,934,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2707D6258CA2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2012, filed 2012-05-10"}},{"date":"2012-04-01","until":"2012-07-01","published":"2012-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 83,256,000,000 United States dollar\", as of 2012-04-01 (until 2012-07-01). Claim clm_6849FB3B6387, https://asof.is/claim/clm_6849FB3B6387, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752312002789/0001157523-12-002789-index.htm.","url":"https://asof.is/claim/clm_6849FB3B6387","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"83,256,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6849FB3B6387","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2012, filed 2012-05-10"}},{"date":"2012-04-01","until":"2012-07-01","published":"2012-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 15,405,000,000 United States dollar\", as of 2012-04-01 (until 2012-07-01). Claim clm_9215DE851890, https://asof.is/claim/clm_9215DE851890, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752312002789/0001157523-12-002789-index.htm.","url":"https://asof.is/claim/clm_9215DE851890","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"15,405,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9215DE851890","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2012, filed 2012-05-10"}},{"date":"2012-04-01","until":"2012-07-01","published":"2012-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 1,794,000,000 United States dollar\", as of 2012-04-01 (until 2012-07-01). Claim clm_94D2F9080CA2, https://asof.is/claim/clm_94D2F9080CA2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752312002789/0001157523-12-002789-index.htm.","url":"https://asof.is/claim/clm_94D2F9080CA2","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"1,794,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_94D2F9080CA2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2012, filed 2012-05-10"}},{"date":"2012-04-01","until":"2012-07-01","published":"2012-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 185,683,000,000 United States dollar\", as of 2012-04-01 (until 2012-07-01). Claim clm_EC6DC19A4817, https://asof.is/claim/clm_EC6DC19A4817, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752312002789/0001157523-12-002789-index.htm.","url":"https://asof.is/claim/clm_EC6DC19A4817","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"185,683,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EC6DC19A4817","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2012, filed 2012-05-10"}},{"date":"2012-05-07","until":"2012-08-06","published":"2012-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 7,488,136,070 shares\", as of 2012-05-07 (until 2012-08-06). Claim clm_E7EE061A0128, https://asof.is/claim/clm_E7EE061A0128, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752312002789/0001157523-12-002789-index.htm.","url":"https://asof.is/claim/clm_E7EE061A0128","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"7,488,136,070 shares","status":"superseded","assertable":true,"id":"clm_E7EE061A0128","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2012, filed 2012-05-10"}},{"date":"2012-07-01","until":"2012-09-30","published":"2012-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 3,253,000,000 United States dollar\", as of 2012-07-01 (until 2012-09-30). Claim clm_14789D5BD7B8, https://asof.is/claim/clm_14789D5BD7B8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752312004450/0001157523-12-004450-index.htm.","url":"https://asof.is/claim/clm_14789D5BD7B8","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"3,253,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_14789D5BD7B8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2012, filed 2012-08-09"}},{"date":"2012-07-01","until":"2012-09-30","published":"2012-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 79,547,000,000 United States dollar\", as of 2012-07-01 (until 2012-09-30). Claim clm_285FE59D4293, https://asof.is/claim/clm_285FE59D4293, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752312004450/0001157523-12-004450-index.htm.","url":"https://asof.is/claim/clm_285FE59D4293","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"79,547,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_285FE59D4293","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2012, filed 2012-08-09"}},{"date":"2012-07-01","until":"2012-09-30","published":"2012-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 3,031,000,000 United States dollar\", as of 2012-07-01 (until 2012-09-30). Claim clm_6DFEA05A3B90, https://asof.is/claim/clm_6DFEA05A3B90, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752312004450/0001157523-12-004450-index.htm.","url":"https://asof.is/claim/clm_6DFEA05A3B90","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"3,031,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6DFEA05A3B90","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2012, filed 2012-08-09"}},{"date":"2012-07-01","until":"2012-09-30","published":"2012-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 15,057,000,000 United States dollar\", as of 2012-07-01 (until 2012-09-30). Claim clm_96D458088120, https://asof.is/claim/clm_96D458088120, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752312004450/0001157523-12-004450-index.htm.","url":"https://asof.is/claim/clm_96D458088120","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"15,057,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_96D458088120","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2012, filed 2012-08-09"}},{"date":"2012-07-01","until":"2012-09-30","published":"2012-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 182,842,000,000 United States dollar\", as of 2012-07-01 (until 2012-09-30). Claim clm_BADFCC83D8A2, https://asof.is/claim/clm_BADFCC83D8A2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752312004450/0001157523-12-004450-index.htm.","url":"https://asof.is/claim/clm_BADFCC83D8A2","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"182,842,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BADFCC83D8A2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2012, filed 2012-08-09"}},{"date":"2012-08-06","until":"2012-11-05","published":"2012-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 7,469,483,622 shares\", as of 2012-08-06 (until 2012-11-05). Claim clm_A75B9DF2A9CB, https://asof.is/claim/clm_A75B9DF2A9CB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000115752312004450/0001157523-12-004450-index.htm.","url":"https://asof.is/claim/clm_A75B9DF2A9CB","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"7,469,483,622 shares","status":"superseded","assertable":true,"id":"clm_A75B9DF2A9CB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2012, filed 2012-08-09"}},{"date":"2012-09-30","until":"2013-03-31","published":"2012-11-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 3,208,000,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_114A0AD1367D, https://asof.is/claim/clm_114A0AD1367D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800312000008/0000078003-12-000008-index.htm.","url":"https://asof.is/claim/clm_114A0AD1367D","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"3,208,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_114A0AD1367D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2012, filed 2012-11-09"}},{"date":"2012-09-30","until":"2012-12-31","published":"2012-11-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 81,703,000,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_6129B47E12DB, https://asof.is/claim/clm_6129B47E12DB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800312000008/0000078003-12-000008-index.htm.","url":"https://asof.is/claim/clm_6129B47E12DB","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"81,703,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6129B47E12DB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2012, filed 2012-11-09"}},{"date":"2012-09-30","until":"2013-03-31","published":"2012-11-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 13,976,000,000 United States dollar\", as of 2012-09-30 (until 2013-03-31). Claim clm_99B393C368BB, https://asof.is/claim/clm_99B393C368BB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800312000008/0000078003-12-000008-index.htm.","url":"https://asof.is/claim/clm_99B393C368BB","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"13,976,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_99B393C368BB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2012, filed 2012-11-09"}},{"date":"2012-09-30","until":"2012-12-31","published":"2012-11-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 182,603,000,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_A7ED16306E0D, https://asof.is/claim/clm_A7ED16306E0D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800312000008/0000078003-12-000008-index.htm.","url":"https://asof.is/claim/clm_A7ED16306E0D","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"182,603,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A7ED16306E0D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2012, filed 2012-11-09"}},{"date":"2012-09-30","until":"2012-12-31","published":"2012-11-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 4,506,000,000 United States dollar\", as of 2012-09-30 (until 2012-12-31). Claim clm_C31FBF66E593, https://asof.is/claim/clm_C31FBF66E593, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800312000008/0000078003-12-000008-index.htm.","url":"https://asof.is/claim/clm_C31FBF66E593","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"4,506,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C31FBF66E593","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2012, filed 2012-11-09"}},{"date":"2012-11-05","until":"2013-02-21","published":"2012-11-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 7,362,573,528 shares\", as of 2012-11-05 (until 2013-02-21). Claim clm_F40205AA9116, https://asof.is/claim/clm_F40205AA9116, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800312000008/0000078003-12-000008-index.htm.","url":"https://asof.is/claim/clm_F40205AA9116","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"7,362,573,528 shares","status":"superseded","assertable":true,"id":"clm_F40205AA9116","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2012, filed 2012-11-09"}},{"date":"2012-12-31","until":"2013-03-31","published":"2013-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 185,798,000,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_1359A112B44F, https://asof.is/claim/clm_1359A112B44F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000006/0000078003-13-000006-index.htm.","url":"https://asof.is/claim/clm_1359A112B44F","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"185,798,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1359A112B44F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2012, filed 2013-02-28"}},{"date":"2012-12-31","until":"2013-03-31","published":"2013-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 10,389,000,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_1DD554187945, https://asof.is/claim/clm_1DD554187945, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000006/0000078003-13-000006-index.htm.","url":"https://asof.is/claim/clm_1DD554187945","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"10,389,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1DD554187945","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2012, filed 2013-02-28"}},{"date":"2012-12-31","until":"2013-12-31","published":"2013-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 14,570,000,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_4F864902CC25, https://asof.is/claim/clm_4F864902CC25, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000006/0000078003-13-000006-index.htm.","url":"https://asof.is/claim/clm_4F864902CC25","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"14,570,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4F864902CC25","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2012, filed 2013-02-28"}},{"date":"2012-12-31","until":"2013-12-31","published":"2013-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer revenue: 58,986,000,000 United States dollar\", as of 2012-12-31 (until 2013-12-31). Claim clm_86543AFFE2B5, https://asof.is/claim/clm_86543AFFE2B5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000006/0000078003-13-000006-index.htm.","url":"https://asof.is/claim/clm_86543AFFE2B5","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"58,986,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_86543AFFE2B5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2012, filed 2013-02-28"}},{"date":"2012-12-31","until":"2013-03-31","published":"2013-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 81,260,000,000 United States dollar\", as of 2012-12-31 (until 2013-03-31). Claim clm_A3DDA007CC97, https://asof.is/claim/clm_A3DDA007CC97, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000006/0000078003-13-000006-index.htm.","url":"https://asof.is/claim/clm_A3DDA007CC97","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"81,260,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A3DDA007CC97","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2012, filed 2013-02-28"}},{"date":"2013-02-21","until":"2013-05-06","published":"2013-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 7,189,061,853 shares\", as of 2013-02-21 (until 2013-05-06). Claim clm_2508F24E3D85, https://asof.is/claim/clm_2508F24E3D85, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000006/0000078003-13-000006-index.htm.","url":"https://asof.is/claim/clm_2508F24E3D85","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"7,189,061,853 shares","status":"superseded","assertable":true,"id":"clm_2508F24E3D85","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2012, filed 2013-02-28"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,134,000,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_3FEE5A5F2C1E, https://asof.is/claim/clm_3FEE5A5F2C1E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000013/0000078003-13-000013-index.htm.","url":"https://asof.is/claim/clm_3FEE5A5F2C1E","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,134,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3FEE5A5F2C1E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2013, filed 2013-05-10"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 187,398,000,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_A90B04A48D17, https://asof.is/claim/clm_A90B04A48D17, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000013/0000078003-13-000013-index.htm.","url":"https://asof.is/claim/clm_A90B04A48D17","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"187,398,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A90B04A48D17","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2013, filed 2013-05-10"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,750,000,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_C5880D6371F1, https://asof.is/claim/clm_C5880D6371F1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000013/0000078003-13-000013-index.htm.","url":"https://asof.is/claim/clm_C5880D6371F1","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,750,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C5880D6371F1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2013, filed 2013-05-10"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 13,500,000,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_CA56F63C64B0, https://asof.is/claim/clm_CA56F63C64B0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000013/0000078003-13-000013-index.htm.","url":"https://asof.is/claim/clm_CA56F63C64B0","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"13,500,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CA56F63C64B0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2013, filed 2013-05-10"}},{"date":"2013-03-31","until":"2013-06-30","published":"2013-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 82,250,000,000 United States dollar\", as of 2013-03-31 (until 2013-06-30). Claim clm_F16241C2251F, https://asof.is/claim/clm_F16241C2251F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000013/0000078003-13-000013-index.htm.","url":"https://asof.is/claim/clm_F16241C2251F","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"82,250,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F16241C2251F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2013, filed 2013-05-10"}},{"date":"2013-05-06","until":"2013-08-05","published":"2013-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 7,093,223,330 shares\", as of 2013-05-06 (until 2013-08-05). Claim clm_82D14D172C47, https://asof.is/claim/clm_82D14D172C47, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000013/0000078003-13-000013-index.htm.","url":"https://asof.is/claim/clm_82D14D172C47","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"7,093,223,330 shares","status":"superseded","assertable":true,"id":"clm_82D14D172C47","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2013, filed 2013-05-10"}},{"date":"2013-06-30","until":"2013-09-29","published":"2013-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 12,973,000,000 United States dollar\", as of 2013-06-30 (until 2013-09-29). Claim clm_4B90345BB070, https://asof.is/claim/clm_4B90345BB070, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000017/0000078003-13-000017-index.htm.","url":"https://asof.is/claim/clm_4B90345BB070","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"12,973,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4B90345BB070","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2013, filed 2013-08-09"}},{"date":"2013-06-30","until":"2013-09-29","published":"2013-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 179,335,000,000 United States dollar\", as of 2013-06-30 (until 2013-09-29). Claim clm_4D7F2F8384DB, https://asof.is/claim/clm_4D7F2F8384DB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000017/0000078003-13-000017-index.htm.","url":"https://asof.is/claim/clm_4D7F2F8384DB","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"179,335,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4D7F2F8384DB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2013, filed 2013-08-09"}},{"date":"2013-06-30","until":"2013-09-29","published":"2013-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 14,095,000,000 United States dollar\", as of 2013-06-30 (until 2013-09-29). Claim clm_81CD54F92CEC, https://asof.is/claim/clm_81CD54F92CEC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000017/0000078003-13-000017-index.htm.","url":"https://asof.is/claim/clm_81CD54F92CEC","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"14,095,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_81CD54F92CEC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2013, filed 2013-08-09"}},{"date":"2013-06-30","until":"2013-09-29","published":"2013-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 78,547,000,000 United States dollar\", as of 2013-06-30 (until 2013-09-29). Claim clm_88525FDF593A, https://asof.is/claim/clm_88525FDF593A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000017/0000078003-13-000017-index.htm.","url":"https://asof.is/claim/clm_88525FDF593A","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"78,547,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_88525FDF593A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2013, filed 2013-08-09"}},{"date":"2013-06-30","until":"2013-09-29","published":"2013-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,436,000,000 United States dollar\", as of 2013-06-30 (until 2013-09-29). Claim clm_C1EA141F1CE4, https://asof.is/claim/clm_C1EA141F1CE4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000017/0000078003-13-000017-index.htm.","url":"https://asof.is/claim/clm_C1EA141F1CE4","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,436,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C1EA141F1CE4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2013, filed 2013-08-09"}},{"date":"2013-08-05","until":"2013-11-04","published":"2013-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 6,620,299,870 shares\", as of 2013-08-05 (until 2013-11-04). Claim clm_06C1E605A0E2, https://asof.is/claim/clm_06C1E605A0E2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000017/0000078003-13-000017-index.htm.","url":"https://asof.is/claim/clm_06C1E605A0E2","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"6,620,299,870 shares","status":"superseded","assertable":true,"id":"clm_06C1E605A0E2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2013, filed 2013-08-09"}},{"date":"2013-09-29","until":"2013-12-31","published":"2013-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 77,969,000,000 United States dollar\", as of 2013-09-29 (until 2013-12-31). Claim clm_136A24C11927, https://asof.is/claim/clm_136A24C11927, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000029/0000078003-13-000029-index.htm.","url":"https://asof.is/claim/clm_136A24C11927","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"77,969,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_136A24C11927","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2013, filed 2013-11-08"}},{"date":"2013-09-29","until":"2014-03-30","published":"2013-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 12,643,000,000 United States dollar\", as of 2013-09-29 (until 2014-03-30). Claim clm_664E9DA37602, https://asof.is/claim/clm_664E9DA37602, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000029/0000078003-13-000029-index.htm.","url":"https://asof.is/claim/clm_664E9DA37602","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"12,643,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_664E9DA37602","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q3 FY2013, filed 2013-11-08"}},{"date":"2013-09-29","until":"2013-12-31","published":"2013-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,052,000,000 United States dollar\", as of 2013-09-29 (until 2013-12-31). Claim clm_C6AE4C700FB2, https://asof.is/claim/clm_C6AE4C700FB2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000029/0000078003-13-000029-index.htm.","url":"https://asof.is/claim/clm_C6AE4C700FB2","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,052,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C6AE4C700FB2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2013, filed 2013-11-08"}},{"date":"2013-09-29","until":"2013-12-31","published":"2013-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 175,521,000,000 United States dollar\", as of 2013-09-29 (until 2013-12-31). Claim clm_E526C6662221, https://asof.is/claim/clm_E526C6662221, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000029/0000078003-13-000029-index.htm.","url":"https://asof.is/claim/clm_E526C6662221","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"175,521,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E526C6662221","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2013, filed 2013-11-08"}},{"date":"2013-09-29","until":"2014-03-30","published":"2013-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,590,000,000 United States dollar\", as of 2013-09-29 (until 2014-03-30). Claim clm_F8E15A270FA3, https://asof.is/claim/clm_F8E15A270FA3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000029/0000078003-13-000029-index.htm.","url":"https://asof.is/claim/clm_F8E15A270FA3","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,590,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F8E15A270FA3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2013, filed 2013-11-08"}},{"date":"2013-11-04","until":"2014-02-21","published":"2013-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 6,481,070,845 shares\", as of 2013-11-04 (until 2014-02-21). Claim clm_534F93F8E85A, https://asof.is/claim/clm_534F93F8E85A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800313000029/0000078003-13-000029-index.htm.","url":"https://asof.is/claim/clm_534F93F8E85A","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"6,481,070,845 shares","status":"superseded","assertable":true,"id":"clm_534F93F8E85A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2013, filed 2013-11-08"}},{"date":"2013-12-31","until":"2014-03-30","published":"2014-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 76,307,000,000 United States dollar\", as of 2013-12-31 (until 2014-03-30). Claim clm_2A92FBF5E510, https://asof.is/claim/clm_2A92FBF5E510, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000018/0000078003-14-000018-index.htm.","url":"https://asof.is/claim/clm_2A92FBF5E510","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"76,307,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2A92FBF5E510","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2013, filed 2014-02-28"}},{"date":"2013-12-31","until":"2014-03-30","published":"2014-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,183,000,000 United States dollar\", as of 2013-12-31 (until 2014-03-30). Claim clm_87E0BBFAE6F4, https://asof.is/claim/clm_87E0BBFAE6F4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000018/0000078003-14-000018-index.htm.","url":"https://asof.is/claim/clm_87E0BBFAE6F4","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,183,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_87E0BBFAE6F4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2013, filed 2014-02-28"}},{"date":"2013-12-31","until":"2014-12-31","published":"2014-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 22,003,000,000 United States dollar\", as of 2013-12-31 (until 2014-12-31). Claim clm_9C263899727D, https://asof.is/claim/clm_9C263899727D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000018/0000078003-14-000018-index.htm.","url":"https://asof.is/claim/clm_9C263899727D","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"22,003,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9C263899727D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2013, filed 2014-02-28"}},{"date":"2013-12-31","until":"2014-03-30","published":"2014-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 172,101,000,000 United States dollar\", as of 2013-12-31 (until 2014-03-30). Claim clm_C9629E6BCCB1, https://asof.is/claim/clm_C9629E6BCCB1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000018/0000078003-14-000018-index.htm.","url":"https://asof.is/claim/clm_C9629E6BCCB1","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"172,101,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C9629E6BCCB1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2013, filed 2014-02-28"}},{"date":"2013-12-31","until":"2016-12-31","published":"2014-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer revenue: 51,584,000,000 United States dollar\", as of 2013-12-31 (until 2016-12-31). Claim clm_FB18F4B76697, https://asof.is/claim/clm_FB18F4B76697, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000018/0000078003-14-000018-index.htm.","url":"https://asof.is/claim/clm_FB18F4B76697","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"51,584,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FB18F4B76697","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-K FY2013, filed 2014-02-28"}},{"date":"2014-02-21","until":"2014-05-05","published":"2014-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 6,382,925,343 shares\", as of 2014-02-21 (until 2014-05-05). Claim clm_2B313AB11302, https://asof.is/claim/clm_2B313AB11302, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000018/0000078003-14-000018-index.htm.","url":"https://asof.is/claim/clm_2B313AB11302","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"6,382,925,343 shares","status":"superseded","assertable":true,"id":"clm_2B313AB11302","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2013, filed 2014-02-28"}},{"date":"2014-03-30","until":"2014-06-29","published":"2014-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 11,353,000,000 United States dollar\", as of 2014-03-30 (until 2014-06-29). Claim clm_0B285A788601, https://asof.is/claim/clm_0B285A788601, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000030/0000078003-14-000030-index.htm.","url":"https://asof.is/claim/clm_0B285A788601","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"11,353,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0B285A788601","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q1 FY2014, filed 2014-05-08"}},{"date":"2014-03-30","until":"2014-06-29","published":"2014-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 171,808,000,000 United States dollar\", as of 2014-03-30 (until 2014-06-29). Claim clm_1C2F1412F1D8, https://asof.is/claim/clm_1C2F1412F1D8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000030/0000078003-14-000030-index.htm.","url":"https://asof.is/claim/clm_1C2F1412F1D8","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"171,808,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1C2F1412F1D8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2014, filed 2014-05-08"}},{"date":"2014-03-30","until":"2014-06-29","published":"2014-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,862,000,000 United States dollar\", as of 2014-03-30 (until 2014-06-29). Claim clm_57F83DACC2BE, https://asof.is/claim/clm_57F83DACC2BE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000030/0000078003-14-000030-index.htm.","url":"https://asof.is/claim/clm_57F83DACC2BE","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,862,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_57F83DACC2BE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2014, filed 2014-05-08"}},{"date":"2014-03-30","until":"2014-06-29","published":"2014-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 77,769,000,000 United States dollar\", as of 2014-03-30 (until 2014-06-29). Claim clm_9D7963A26BA2, https://asof.is/claim/clm_9D7963A26BA2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000030/0000078003-14-000030-index.htm.","url":"https://asof.is/claim/clm_9D7963A26BA2","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"77,769,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9D7963A26BA2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2014, filed 2014-05-08"}},{"date":"2014-03-30","until":"2014-06-29","published":"2014-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,329,000,000 United States dollar\", as of 2014-03-30 (until 2014-06-29). Claim clm_A4396B55E390, https://asof.is/claim/clm_A4396B55E390, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000030/0000078003-14-000030-index.htm.","url":"https://asof.is/claim/clm_A4396B55E390","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,329,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A4396B55E390","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2014, filed 2014-05-08"}},{"date":"2014-05-05","until":"2014-08-04","published":"2014-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 6,378,718,293 shares\", as of 2014-05-05 (until 2014-08-04). Claim clm_78332E3867E8, https://asof.is/claim/clm_78332E3867E8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000030/0000078003-14-000030-index.htm.","url":"https://asof.is/claim/clm_78332E3867E8","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"6,378,718,293 shares","status":"superseded","assertable":true,"id":"clm_78332E3867E8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2014, filed 2014-05-08"}},{"date":"2014-06-29","until":"2014-09-28","published":"2014-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,912,000,000 United States dollar\", as of 2014-06-29 (until 2014-09-28). Claim clm_2C7E3E0F8114, https://asof.is/claim/clm_2C7E3E0F8114, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000039/0000078003-14-000039-index.htm.","url":"https://asof.is/claim/clm_2C7E3E0F8114","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,912,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2C7E3E0F8114","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2014, filed 2014-08-07"}},{"date":"2014-06-29","until":"2017-07-02","published":"2014-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 12,773,000,000 United States dollar\", as of 2014-06-29 (until 2017-07-02). Claim clm_2F8C36CCD5B2, https://asof.is/claim/clm_2F8C36CCD5B2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000039/0000078003-14-000039-index.htm.","url":"https://asof.is/claim/clm_2F8C36CCD5B2","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"12,773,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2F8C36CCD5B2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:SalesRevenueNet in 10-Q Q2 FY2014, filed 2014-08-07"}},{"date":"2014-06-29","until":"2014-09-28","published":"2014-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 76,633,000,000 United States dollar\", as of 2014-06-29 (until 2014-09-28). Claim clm_3878EDF44916, https://asof.is/claim/clm_3878EDF44916, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000039/0000078003-14-000039-index.htm.","url":"https://asof.is/claim/clm_3878EDF44916","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"76,633,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3878EDF44916","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2014, filed 2014-08-07"}},{"date":"2014-06-29","until":"2014-09-28","published":"2014-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 172,612,000,000 United States dollar\", as of 2014-06-29 (until 2014-09-28). Claim clm_8F66FB414C3B, https://asof.is/claim/clm_8F66FB414C3B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000039/0000078003-14-000039-index.htm.","url":"https://asof.is/claim/clm_8F66FB414C3B","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"172,612,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8F66FB414C3B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2014, filed 2014-08-07"}},{"date":"2014-06-29","until":"2014-09-28","published":"2014-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 3,406,000,000 United States dollar\", as of 2014-06-29 (until 2014-09-28). Claim clm_DBDA2D6605F0, https://asof.is/claim/clm_DBDA2D6605F0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000039/0000078003-14-000039-index.htm.","url":"https://asof.is/claim/clm_DBDA2D6605F0","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"3,406,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DBDA2D6605F0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2014, filed 2014-08-07"}},{"date":"2014-08-04","until":"2014-11-03","published":"2014-08-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 6,340,863,126 shares\", as of 2014-08-04 (until 2014-11-03). Claim clm_365E507D018D, https://asof.is/claim/clm_365E507D018D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000039/0000078003-14-000039-index.htm.","url":"https://asof.is/claim/clm_365E507D018D","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"6,340,863,126 shares","status":"superseded","assertable":true,"id":"clm_365E507D018D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2014, filed 2014-08-07"}},{"date":"2014-09-28","until":"2014-12-31","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,437,000,000 United States dollar\", as of 2014-09-28 (until 2014-12-31). Claim clm_0D501BD86F36, https://asof.is/claim/clm_0D501BD86F36, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000046/0000078003-14-000046-index.htm.","url":"https://asof.is/claim/clm_0D501BD86F36","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,437,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0D501BD86F36","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2014, filed 2014-11-06"}},{"date":"2014-09-28","until":"2014-12-31","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 77,988,000,000 United States dollar\", as of 2014-09-28 (until 2014-12-31). Claim clm_C4EF14DE31D0, https://asof.is/claim/clm_C4EF14DE31D0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000046/0000078003-14-000046-index.htm.","url":"https://asof.is/claim/clm_C4EF14DE31D0","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"77,988,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C4EF14DE31D0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2014, filed 2014-11-06"}},{"date":"2014-09-28","until":"2015-03-29","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,666,000,000 United States dollar\", as of 2014-09-28 (until 2015-03-29). Claim clm_CF1952B47B0A, https://asof.is/claim/clm_CF1952B47B0A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000046/0000078003-14-000046-index.htm.","url":"https://asof.is/claim/clm_CF1952B47B0A","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,666,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CF1952B47B0A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2014, filed 2014-11-06"}},{"date":"2014-09-28","until":"2014-12-31","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 171,362,000,000 United States dollar\", as of 2014-09-28 (until 2014-12-31). Claim clm_D87DB981D2E9, https://asof.is/claim/clm_D87DB981D2E9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000046/0000078003-14-000046-index.htm.","url":"https://asof.is/claim/clm_D87DB981D2E9","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"171,362,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D87DB981D2E9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2014, filed 2014-11-06"}},{"date":"2014-11-03","until":"2015-02-20","published":"2014-11-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 6,300,657,237 shares\", as of 2014-11-03 (until 2015-02-20). Claim clm_8E2F42A6A3FA, https://asof.is/claim/clm_8E2F42A6A3FA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800314000046/0000078003-14-000046-index.htm.","url":"https://asof.is/claim/clm_8E2F42A6A3FA","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"6,300,657,237 shares","status":"superseded","assertable":true,"id":"clm_8E2F42A6A3FA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2014, filed 2014-11-06"}},{"date":"2014-12-31","until":"2015-03-29","published":"2015-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 3,343,000,000 United States dollar\", as of 2014-12-31 (until 2015-03-29). Claim clm_20A2EAD6F31C, https://asof.is/claim/clm_20A2EAD6F31C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800315000014/0000078003-15-000014-index.htm.","url":"https://asof.is/claim/clm_20A2EAD6F31C","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"3,343,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_20A2EAD6F31C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2014, filed 2015-02-27"}},{"date":"2014-12-31","until":"2015-12-31","published":"2015-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 9,135,000,000 United States dollar\", as of 2014-12-31 (until 2015-12-31). Claim clm_2314E443626D, https://asof.is/claim/clm_2314E443626D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800315000014/0000078003-15-000014-index.htm.","url":"https://asof.is/claim/clm_2314E443626D","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"9,135,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2314E443626D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2014, filed 2015-02-27"}},{"date":"2014-12-31","until":"2015-03-29","published":"2015-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 169,274,000,000 United States dollar\", as of 2014-12-31 (until 2015-03-29). Claim clm_4E1E21B37207, https://asof.is/claim/clm_4E1E21B37207, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800315000014/0000078003-15-000014-index.htm.","url":"https://asof.is/claim/clm_4E1E21B37207","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"169,274,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4E1E21B37207","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2014, filed 2015-02-27"}},{"date":"2014-12-31","until":"2015-03-29","published":"2015-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 71,301,000,000 United States dollar\", as of 2014-12-31 (until 2015-03-29). Claim clm_7D8DA48BF745, https://asof.is/claim/clm_7D8DA48BF745, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800315000014/0000078003-15-000014-index.htm.","url":"https://asof.is/claim/clm_7D8DA48BF745","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"71,301,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7D8DA48BF745","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2014, filed 2015-02-27"}},{"date":"2015-02-20","until":"2015-05-04","published":"2015-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 6,128,855,392 shares\", as of 2015-02-20 (until 2015-05-04). Claim clm_FA6D9862BA40, https://asof.is/claim/clm_FA6D9862BA40, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800315000014/0000078003-15-000014-index.htm.","url":"https://asof.is/claim/clm_FA6D9862BA40","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"6,128,855,392 shares","status":"superseded","assertable":true,"id":"clm_FA6D9862BA40","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2014, filed 2015-02-27"}},{"date":"2015-03-29","until":"2015-06-28","published":"2015-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 67,304,000,000 United States dollar\", as of 2015-03-29 (until 2015-06-28). Claim clm_344738B18171, https://asof.is/claim/clm_344738B18171, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800315000026/0000078003-15-000026-index.htm.","url":"https://asof.is/claim/clm_344738B18171","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"67,304,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_344738B18171","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2015, filed 2015-05-07"}},{"date":"2015-03-29","until":"2015-06-28","published":"2015-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,376,000,000 United States dollar\", as of 2015-03-29 (until 2015-06-28). Claim clm_476B8B941995, https://asof.is/claim/clm_476B8B941995, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800315000026/0000078003-15-000026-index.htm.","url":"https://asof.is/claim/clm_476B8B941995","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,376,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_476B8B941995","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2015, filed 2015-05-07"}},{"date":"2015-03-29","until":"2015-06-28","published":"2015-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 160,640,000,000 United States dollar\", as of 2015-03-29 (until 2015-06-28). Claim clm_7084E3C23CBF, https://asof.is/claim/clm_7084E3C23CBF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800315000026/0000078003-15-000026-index.htm.","url":"https://asof.is/claim/clm_7084E3C23CBF","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"160,640,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7084E3C23CBF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2015, filed 2015-05-07"}},{"date":"2015-03-29","until":"2015-06-28","published":"2015-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 3,563,000,000 United States dollar\", as of 2015-03-29 (until 2015-06-28). Claim clm_F28D1FEB0CD7, https://asof.is/claim/clm_F28D1FEB0CD7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800315000026/0000078003-15-000026-index.htm.","url":"https://asof.is/claim/clm_F28D1FEB0CD7","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"3,563,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F28D1FEB0CD7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2015, filed 2015-05-07"}},{"date":"2015-05-04","until":"2015-08-03","published":"2015-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 6,157,669,933 shares\", as of 2015-05-04 (until 2015-08-03). Claim clm_B92B2BC37C1D, https://asof.is/claim/clm_B92B2BC37C1D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800315000026/0000078003-15-000026-index.htm.","url":"https://asof.is/claim/clm_B92B2BC37C1D","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"6,157,669,933 shares","status":"superseded","assertable":true,"id":"clm_B92B2BC37C1D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2015, filed 2015-05-07"}},{"date":"2015-06-28","until":"2015-09-27","published":"2015-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 160,878,000,000 United States dollar\", as of 2015-06-28 (until 2015-09-27). Claim clm_17BB3326A8B7, https://asof.is/claim/clm_17BB3326A8B7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800315000034/0000078003-15-000034-index.htm.","url":"https://asof.is/claim/clm_17BB3326A8B7","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"160,878,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_17BB3326A8B7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2015, filed 2015-08-06"}},{"date":"2015-06-28","until":"2015-09-27","published":"2015-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,626,000,000 United States dollar\", as of 2015-06-28 (until 2015-09-27). Claim clm_5B6F8F96CEAB, https://asof.is/claim/clm_5B6F8F96CEAB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800315000034/0000078003-15-000034-index.htm.","url":"https://asof.is/claim/clm_5B6F8F96CEAB","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,626,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5B6F8F96CEAB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2015, filed 2015-08-06"}},{"date":"2015-06-28","until":"2015-09-27","published":"2015-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 66,894,000,000 United States dollar\", as of 2015-06-28 (until 2015-09-27). Claim clm_C9524E417685, https://asof.is/claim/clm_C9524E417685, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800315000034/0000078003-15-000034-index.htm.","url":"https://asof.is/claim/clm_C9524E417685","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"66,894,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C9524E417685","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2015, filed 2015-08-06"}},{"date":"2015-06-28","until":"2015-09-27","published":"2015-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 3,670,000,000 United States dollar\", as of 2015-06-28 (until 2015-09-27). Claim clm_DB55364508A1, https://asof.is/claim/clm_DB55364508A1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800315000034/0000078003-15-000034-index.htm.","url":"https://asof.is/claim/clm_DB55364508A1","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"3,670,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DB55364508A1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2015, filed 2015-08-06"}},{"date":"2015-08-03","until":"2015-11-02","published":"2015-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 6,167,347,758 shares\", as of 2015-08-03 (until 2015-11-02). Claim clm_2036D5297194, https://asof.is/claim/clm_2036D5297194, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800315000034/0000078003-15-000034-index.htm.","url":"https://asof.is/claim/clm_2036D5297194","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"6,167,347,758 shares","status":"superseded","assertable":true,"id":"clm_2036D5297194","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2015, filed 2015-08-06"}},{"date":"2015-09-27","until":"2016-04-03","published":"2015-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,130,000,000 United States dollar\", as of 2015-09-27 (until 2016-04-03). Claim clm_275A1C9FC14D, https://asof.is/claim/clm_275A1C9FC14D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800315000051/0000078003-15-000051-index.htm.","url":"https://asof.is/claim/clm_275A1C9FC14D","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,130,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_275A1C9FC14D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2015, filed 2015-11-05"}},{"date":"2015-09-27","until":"2015-12-31","published":"2015-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 66,838,000,000 United States dollar\", as of 2015-09-27 (until 2015-12-31). Claim clm_51F5D609D71C, https://asof.is/claim/clm_51F5D609D71C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800315000051/0000078003-15-000051-index.htm.","url":"https://asof.is/claim/clm_51F5D609D71C","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"66,838,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_51F5D609D71C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2015, filed 2015-11-05"}},{"date":"2015-09-27","until":"2015-12-31","published":"2015-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 170,867,000,000 United States dollar\", as of 2015-09-27 (until 2015-12-31). Claim clm_B192E3B59FA9, https://asof.is/claim/clm_B192E3B59FA9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800315000051/0000078003-15-000051-index.htm.","url":"https://asof.is/claim/clm_B192E3B59FA9","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"170,867,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B192E3B59FA9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2015, filed 2015-11-05"}},{"date":"2015-09-27","until":"2015-12-31","published":"2015-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 3,099,000,000 United States dollar\", as of 2015-09-27 (until 2015-12-31). Claim clm_DB8531E2B832, https://asof.is/claim/clm_DB8531E2B832, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800315000051/0000078003-15-000051-index.htm.","url":"https://asof.is/claim/clm_DB8531E2B832","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"3,099,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DB8531E2B832","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2015, filed 2015-11-05"}},{"date":"2015-11-02","until":"2016-02-25","published":"2015-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 6,173,001,952 shares\", as of 2015-11-02 (until 2016-02-25). Claim clm_1D63F69A225E, https://asof.is/claim/clm_1D63F69A225E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800315000051/0000078003-15-000051-index.htm.","url":"https://asof.is/claim/clm_1D63F69A225E","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"6,173,001,952 shares","status":"superseded","assertable":true,"id":"clm_1D63F69A225E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2015, filed 2015-11-05"}},{"date":"2015-12-31","until":"2016-04-03","published":"2016-02-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 64,720,000,000 United States dollar\", as of 2015-12-31 (until 2016-04-03). Claim clm_252A99116625, https://asof.is/claim/clm_252A99116625, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800316000077/0000078003-16-000077-index.htm.","url":"https://asof.is/claim/clm_252A99116625","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"64,720,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_252A99116625","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2015, filed 2016-02-29"}},{"date":"2015-12-31","until":"2016-12-31","published":"2016-02-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 6,960,000,000 United States dollar\", as of 2015-12-31 (until 2016-12-31). Claim clm_2F829FFC8699, https://asof.is/claim/clm_2F829FFC8699, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800316000077/0000078003-16-000077-index.htm.","url":"https://asof.is/claim/clm_2F829FFC8699","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"6,960,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2F829FFC8699","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2015, filed 2016-02-29"}},{"date":"2015-12-31","until":"2016-04-03","published":"2016-02-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 167,460,000,000 United States dollar\", as of 2015-12-31 (until 2016-04-03). Claim clm_934C659C5684, https://asof.is/claim/clm_934C659C5684, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800316000077/0000078003-16-000077-index.htm.","url":"https://asof.is/claim/clm_934C659C5684","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"167,460,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_934C659C5684","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2015, filed 2016-02-29"}},{"date":"2015-12-31","until":"2016-04-03","published":"2016-02-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 3,641,000,000 United States dollar\", as of 2015-12-31 (until 2016-04-03). Claim clm_99E7A1D87708, https://asof.is/claim/clm_99E7A1D87708, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800316000077/0000078003-16-000077-index.htm.","url":"https://asof.is/claim/clm_99E7A1D87708","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"3,641,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_99E7A1D87708","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2015, filed 2016-02-29"}},{"date":"2016-02-25","until":"2016-05-09","published":"2016-02-29","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 6,184,139,991 shares\", as of 2016-02-25 (until 2016-05-09). Claim clm_339C85F69000, https://asof.is/claim/clm_339C85F69000, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800316000077/0000078003-16-000077-index.htm.","url":"https://asof.is/claim/clm_339C85F69000","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"6,184,139,991 shares","status":"superseded","assertable":true,"id":"clm_339C85F69000","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2015, filed 2016-02-29"}},{"date":"2016-04-03","until":"2016-07-03","published":"2016-05-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 63,068,000,000 United States dollar\", as of 2016-04-03 (until 2016-07-03). Claim clm_0E721F182CD6, https://asof.is/claim/clm_0E721F182CD6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800316000096/0000078003-16-000096-index.htm.","url":"https://asof.is/claim/clm_0E721F182CD6","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"63,068,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0E721F182CD6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2016, filed 2016-05-12"}},{"date":"2016-04-03","until":"2016-07-03","published":"2016-05-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 3,016,000,000 United States dollar\", as of 2016-04-03 (until 2016-07-03). Claim clm_178F37D855C5, https://asof.is/claim/clm_178F37D855C5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800316000096/0000078003-16-000096-index.htm.","url":"https://asof.is/claim/clm_178F37D855C5","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"3,016,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_178F37D855C5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2016, filed 2016-05-12"}},{"date":"2016-04-03","until":"2016-07-03","published":"2016-05-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 162,929,000,000 United States dollar\", as of 2016-04-03 (until 2016-07-03). Claim clm_186B8C28EC72, https://asof.is/claim/clm_186B8C28EC72, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800316000096/0000078003-16-000096-index.htm.","url":"https://asof.is/claim/clm_186B8C28EC72","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"162,929,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_186B8C28EC72","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2016, filed 2016-05-12"}},{"date":"2016-04-03","until":"2016-07-03","published":"2016-05-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,561,000,000 United States dollar\", as of 2016-04-03 (until 2016-07-03). Claim clm_516D3F83C6CE, https://asof.is/claim/clm_516D3F83C6CE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800316000096/0000078003-16-000096-index.htm.","url":"https://asof.is/claim/clm_516D3F83C6CE","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,561,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_516D3F83C6CE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2016, filed 2016-05-12"}},{"date":"2016-05-09","until":"2016-08-08","published":"2016-05-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 6,064,849,361 shares\", as of 2016-05-09 (until 2016-08-08). Claim clm_AE575BC37874, https://asof.is/claim/clm_AE575BC37874, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800316000096/0000078003-16-000096-index.htm.","url":"https://asof.is/claim/clm_AE575BC37874","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"6,064,849,361 shares","status":"superseded","assertable":true,"id":"clm_AE575BC37874","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2016, filed 2016-05-12"}},{"date":"2016-07-03","until":"2016-10-02","published":"2016-08-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,019,000,000 United States dollar\", as of 2016-07-03 (until 2016-10-02). Claim clm_430BA807FB18, https://asof.is/claim/clm_430BA807FB18, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800316000105/0000078003-16-000105-index.htm.","url":"https://asof.is/claim/clm_430BA807FB18","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,019,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_430BA807FB18","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2016, filed 2016-08-11"}},{"date":"2016-07-03","until":"2016-10-02","published":"2016-08-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 170,658,000,000 United States dollar\", as of 2016-07-03 (until 2016-10-02). Claim clm_64FEAC6FDDA8, https://asof.is/claim/clm_64FEAC6FDDA8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800316000105/0000078003-16-000105-index.htm.","url":"https://asof.is/claim/clm_64FEAC6FDDA8","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"170,658,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_64FEAC6FDDA8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2016, filed 2016-08-11"}},{"date":"2016-07-03","until":"2016-10-02","published":"2016-08-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 3,411,000,000 United States dollar\", as of 2016-07-03 (until 2016-10-02). Claim clm_8EB5857AD2F9, https://asof.is/claim/clm_8EB5857AD2F9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800316000105/0000078003-16-000105-index.htm.","url":"https://asof.is/claim/clm_8EB5857AD2F9","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"3,411,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8EB5857AD2F9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2016, filed 2016-08-11"}},{"date":"2016-07-03","until":"2016-10-02","published":"2016-08-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 62,769,000,000 United States dollar\", as of 2016-07-03 (until 2016-10-02). Claim clm_BC24A3A22592, https://asof.is/claim/clm_BC24A3A22592, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800316000105/0000078003-16-000105-index.htm.","url":"https://asof.is/claim/clm_BC24A3A22592","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"62,769,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BC24A3A22592","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2016, filed 2016-08-11"}},{"date":"2016-08-08","until":"2016-11-07","published":"2016-08-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 6,065,652,424 shares\", as of 2016-08-08 (until 2016-11-07). Claim clm_AEC1B41E35E3, https://asof.is/claim/clm_AEC1B41E35E3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800316000105/0000078003-16-000105-index.htm.","url":"https://asof.is/claim/clm_AEC1B41E35E3","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"6,065,652,424 shares","status":"superseded","assertable":true,"id":"clm_AEC1B41E35E3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2016, filed 2016-08-11"}},{"date":"2016-10-02","until":"2016-12-31","published":"2016-11-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,094,000,000 United States dollar\", as of 2016-10-02 (until 2016-12-31). Claim clm_364CB5A67147, https://asof.is/claim/clm_364CB5A67147, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800316000113/0000078003-16-000113-index.htm.","url":"https://asof.is/claim/clm_364CB5A67147","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,094,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_364CB5A67147","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2016, filed 2016-11-10"}},{"date":"2016-10-02","until":"2016-12-31","published":"2016-11-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 178,430,000,000 United States dollar\", as of 2016-10-02 (until 2016-12-31). Claim clm_C3D9C7B71A95, https://asof.is/claim/clm_C3D9C7B71A95, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800316000113/0000078003-16-000113-index.htm.","url":"https://asof.is/claim/clm_C3D9C7B71A95","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"178,430,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C3D9C7B71A95","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2016, filed 2016-11-10"}},{"date":"2016-10-02","until":"2016-12-31","published":"2016-11-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 63,306,000,000 United States dollar\", as of 2016-10-02 (until 2016-12-31). Claim clm_E5A62E7278F7, https://asof.is/claim/clm_E5A62E7278F7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800316000113/0000078003-16-000113-index.htm.","url":"https://asof.is/claim/clm_E5A62E7278F7","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"63,306,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E5A62E7278F7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2016, filed 2016-11-10"}},{"date":"2016-10-02","until":"2017-04-02","published":"2016-11-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 1,320,000,000 United States dollar\", as of 2016-10-02 (until 2017-04-02). Claim clm_F3336EBA2EA3, https://asof.is/claim/clm_F3336EBA2EA3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800316000113/0000078003-16-000113-index.htm.","url":"https://asof.is/claim/clm_F3336EBA2EA3","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"1,320,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F3336EBA2EA3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2016, filed 2016-11-10"}},{"date":"2016-11-07","until":"2017-02-21","published":"2016-11-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 6,068,355,132 shares\", as of 2016-11-07 (until 2017-02-21). Claim clm_FC1C31C55F6B, https://asof.is/claim/clm_FC1C31C55F6B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800316000113/0000078003-16-000113-index.htm.","url":"https://asof.is/claim/clm_FC1C31C55F6B","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"6,068,355,132 shares","status":"superseded","assertable":true,"id":"clm_FC1C31C55F6B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2016, filed 2016-11-10"}},{"date":"2016-12-31","until":"2017-12-31","published":"2019-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer revenue: 52,824,000,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_032BE9565D4B, https://asof.is/claim/clm_032BE9565D4B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000015/0000078003-19-000015-index.htm.","url":"https://asof.is/claim/clm_032BE9565D4B","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"52,824,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_032BE9565D4B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2018, filed 2019-02-28"}},{"date":"2016-12-31","until":"2017-04-02","published":"2017-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,595,000,000 United States dollar\", as of 2016-12-31 (until 2017-04-02). Claim clm_3D25286B815A, https://asof.is/claim/clm_3D25286B815A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800317000014/0000078003-17-000014-index.htm.","url":"https://asof.is/claim/clm_3D25286B815A","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,595,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3D25286B815A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2016, filed 2017-02-23"}},{"date":"2016-12-31","until":"2017-04-02","published":"2017-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 171,615,000,000 United States dollar\", as of 2016-12-31 (until 2017-04-02). Claim clm_4E84937F0829, https://asof.is/claim/clm_4E84937F0829, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800317000014/0000078003-17-000014-index.htm.","url":"https://asof.is/claim/clm_4E84937F0829","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"171,615,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4E84937F0829","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2016, filed 2017-02-23"}},{"date":"2016-12-31","until":"2017-12-31","published":"2017-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 7,215,000,000 United States dollar\", as of 2016-12-31 (until 2017-12-31). Claim clm_85A65F179A0C, https://asof.is/claim/clm_85A65F179A0C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800317000014/0000078003-17-000014-index.htm.","url":"https://asof.is/claim/clm_85A65F179A0C","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"7,215,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_85A65F179A0C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2016, filed 2017-02-23"}},{"date":"2016-12-31","until":"2017-04-02","published":"2017-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 59,544,000,000 United States dollar\", as of 2016-12-31 (until 2017-04-02). Claim clm_D867E8328A40, https://asof.is/claim/clm_D867E8328A40, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800317000014/0000078003-17-000014-index.htm.","url":"https://asof.is/claim/clm_D867E8328A40","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"59,544,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D867E8328A40","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2016, filed 2017-02-23"}},{"date":"2017-02-21","until":"2017-05-08","published":"2017-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,951,872,174 shares\", as of 2017-02-21 (until 2017-05-08). Claim clm_8FD51B6B7E8B, https://asof.is/claim/clm_8FD51B6B7E8B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800317000014/0000078003-17-000014-index.htm.","url":"https://asof.is/claim/clm_8FD51B6B7E8B","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,951,872,174 shares","status":"superseded","assertable":true,"id":"clm_8FD51B6B7E8B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2016, filed 2017-02-23"}},{"date":"2017-04-02","until":"2017-07-02","published":"2017-05-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 4,057,000,000 United States dollar\", as of 2017-04-02 (until 2017-07-02). Claim clm_2AB57DEE47F5, https://asof.is/claim/clm_2AB57DEE47F5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800317000024/0000078003-17-000024-index.htm.","url":"https://asof.is/claim/clm_2AB57DEE47F5","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"4,057,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2AB57DEE47F5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2017, filed 2017-05-11"}},{"date":"2017-04-02","until":"2017-07-02","published":"2017-05-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 3,121,000,000 United States dollar\", as of 2017-04-02 (until 2017-07-02). Claim clm_AB7A95B18715, https://asof.is/claim/clm_AB7A95B18715, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800317000024/0000078003-17-000024-index.htm.","url":"https://asof.is/claim/clm_AB7A95B18715","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"3,121,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AB7A95B18715","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2017, filed 2017-05-11"}},{"date":"2017-04-02","until":"2017-07-02","published":"2017-05-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 168,784,000,000 United States dollar\", as of 2017-04-02 (until 2017-07-02). Claim clm_C1E553F27A81, https://asof.is/claim/clm_C1E553F27A81, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800317000024/0000078003-17-000024-index.htm.","url":"https://asof.is/claim/clm_C1E553F27A81","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"168,784,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C1E553F27A81","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2017, filed 2017-05-11"}},{"date":"2017-04-02","until":"2017-07-02","published":"2017-05-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 58,435,000,000 United States dollar\", as of 2017-04-02 (until 2017-07-02). Claim clm_FDECD3A573CD, https://asof.is/claim/clm_FDECD3A573CD, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800317000024/0000078003-17-000024-index.htm.","url":"https://asof.is/claim/clm_FDECD3A573CD","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"58,435,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FDECD3A573CD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2017, filed 2017-05-11"}},{"date":"2017-05-08","until":"2017-08-07","published":"2017-05-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,967,844,470 shares\", as of 2017-05-08 (until 2017-08-07). Claim clm_0C8B24EB4CB5, https://asof.is/claim/clm_0C8B24EB4CB5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800317000024/0000078003-17-000024-index.htm.","url":"https://asof.is/claim/clm_0C8B24EB4CB5","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,967,844,470 shares","status":"superseded","assertable":true,"id":"clm_0C8B24EB4CB5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2017, filed 2017-05-11"}},{"date":"2017-07-02","until":"2017-10-01","published":"2017-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 3,073,000,000 United States dollar\", as of 2017-07-02 (until 2017-10-01). Claim clm_45F57DEB3C61, https://asof.is/claim/clm_45F57DEB3C61, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800317000039/0000078003-17-000039-index.htm.","url":"https://asof.is/claim/clm_45F57DEB3C61","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"3,073,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_45F57DEB3C61","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2017, filed 2017-08-10"}},{"date":"2017-07-02","until":"2017-10-01","published":"2017-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 168,558,000,000 United States dollar\", as of 2017-07-02 (until 2017-10-01). Claim clm_79FE1EEF8413, https://asof.is/claim/clm_79FE1EEF8413, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800317000039/0000078003-17-000039-index.htm.","url":"https://asof.is/claim/clm_79FE1EEF8413","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"168,558,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_79FE1EEF8413","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2017, filed 2017-08-10"}},{"date":"2017-07-02","until":"2017-10-01","published":"2017-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 58,368,000,000 United States dollar\", as of 2017-07-02 (until 2017-10-01). Claim clm_8A0B9C303BC8, https://asof.is/claim/clm_8A0B9C303BC8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800317000039/0000078003-17-000039-index.htm.","url":"https://asof.is/claim/clm_8A0B9C303BC8","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"58,368,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8A0B9C303BC8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2017, filed 2017-08-10"}},{"date":"2017-07-02","until":"2017-10-01","published":"2018-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 12,896,000,000 United States dollar\", as of 2017-07-02 (until 2017-10-01). Claim clm_B6A35B59BF8C, https://asof.is/claim/clm_B6A35B59BF8C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000070/0000078003-18-000070-index.htm.","url":"https://asof.is/claim/clm_B6A35B59BF8C","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"12,896,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B6A35B59BF8C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2018, filed 2018-08-09"}},{"date":"2017-07-02","until":"2017-10-01","published":"2017-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,585,000,000 United States dollar\", as of 2017-07-02 (until 2017-10-01). Claim clm_D38716C8D3D8, https://asof.is/claim/clm_D38716C8D3D8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800317000039/0000078003-17-000039-index.htm.","url":"https://asof.is/claim/clm_D38716C8D3D8","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,585,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D38716C8D3D8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2017, filed 2017-08-10"}},{"date":"2017-08-07","until":"2017-11-06","published":"2017-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,947,349,054 shares\", as of 2017-08-07 (until 2017-11-06). Claim clm_4D32FB5F43AF, https://asof.is/claim/clm_4D32FB5F43AF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800317000039/0000078003-17-000039-index.htm.","url":"https://asof.is/claim/clm_4D32FB5F43AF","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,947,349,054 shares","status":"superseded","assertable":true,"id":"clm_4D32FB5F43AF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2017, filed 2017-08-10"}},{"date":"2017-10-01","until":"2017-12-31","published":"2017-11-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 172,151,000,000 United States dollar\", as of 2017-10-01 (until 2017-12-31). Claim clm_28376A9262CC, https://asof.is/claim/clm_28376A9262CC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800317000049/0000078003-17-000049-index.htm.","url":"https://asof.is/claim/clm_28376A9262CC","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"172,151,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_28376A9262CC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2017, filed 2017-11-09"}},{"date":"2017-10-01","until":"2017-12-31","published":"2017-11-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,779,000,000 United States dollar\", as of 2017-10-01 (until 2017-12-31). Claim clm_2F6E0DD6ECA2, https://asof.is/claim/clm_2F6E0DD6ECA2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800317000049/0000078003-17-000049-index.htm.","url":"https://asof.is/claim/clm_2F6E0DD6ECA2","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,779,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2F6E0DD6ECA2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2017, filed 2017-11-09"}},{"date":"2017-10-01","until":"2018-04-01","published":"2018-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 13,168,000,000 United States dollar\", as of 2017-10-01 (until 2018-04-01). Claim clm_8058BCAD20C5, https://asof.is/claim/clm_8058BCAD20C5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000091/0000078003-18-000091-index.htm.","url":"https://asof.is/claim/clm_8058BCAD20C5","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"13,168,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8058BCAD20C5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2018, filed 2018-11-08"}},{"date":"2017-10-01","until":"2018-04-01","published":"2017-11-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,840,000,000 United States dollar\", as of 2017-10-01 (until 2018-04-01). Claim clm_93F6082A0871, https://asof.is/claim/clm_93F6082A0871, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800317000049/0000078003-17-000049-index.htm.","url":"https://asof.is/claim/clm_93F6082A0871","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,840,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_93F6082A0871","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2017, filed 2017-11-09"}},{"date":"2017-10-01","until":"2017-12-31","published":"2017-11-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 60,770,000,000 United States dollar\", as of 2017-10-01 (until 2017-12-31). Claim clm_C8EDBAF587BD, https://asof.is/claim/clm_C8EDBAF587BD, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800317000049/0000078003-17-000049-index.htm.","url":"https://asof.is/claim/clm_C8EDBAF587BD","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"60,770,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C8EDBAF587BD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2017, filed 2017-11-09"}},{"date":"2017-11-06","until":"2018-02-20","published":"2017-11-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,960,707,317 shares\", as of 2017-11-06 (until 2018-02-20). Claim clm_00ABF8F6E7CC, https://asof.is/claim/clm_00ABF8F6E7CC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800317000049/0000078003-17-000049-index.htm.","url":"https://asof.is/claim/clm_00ABF8F6E7CC","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,960,707,317 shares","status":"superseded","assertable":true,"id":"clm_00ABF8F6E7CC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2017, filed 2017-11-09"}},{"date":"2017-12-31","until":"2018-04-01","published":"2018-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 71,308,000,000 United States dollar\", as of 2017-12-31 (until 2018-04-01). Claim clm_1074604C6B48, https://asof.is/claim/clm_1074604C6B48, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000027/0000078003-18-000027-index.htm.","url":"https://asof.is/claim/clm_1074604C6B48","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"71,308,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1074604C6B48","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2017, filed 2018-02-22"}},{"date":"2017-12-31","until":"2018-04-01","published":"2018-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,342,000,000 United States dollar\", as of 2017-12-31 (until 2018-04-01). Claim clm_46133C25B60E, https://asof.is/claim/clm_46133C25B60E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000027/0000078003-18-000027-index.htm.","url":"https://asof.is/claim/clm_46133C25B60E","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,342,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_46133C25B60E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2017, filed 2018-02-22"}},{"date":"2017-12-31","until":"2018-12-31","published":"2018-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 21,308,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_909812E45671, https://asof.is/claim/clm_909812E45671, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000027/0000078003-18-000027-index.htm.","url":"https://asof.is/claim/clm_909812E45671","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"21,308,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_909812E45671","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2017, filed 2018-02-22"}},{"date":"2017-12-31","until":"2018-12-31","published":"2019-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer revenue: 52,546,000,000 United States dollar\", as of 2017-12-31 (until 2018-12-31). Claim clm_C3C550AB2D1A, https://asof.is/claim/clm_C3C550AB2D1A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000015/0000078003-19-000015-index.htm.","url":"https://asof.is/claim/clm_C3C550AB2D1A","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"52,546,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C3C550AB2D1A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2018, filed 2019-02-28"}},{"date":"2017-12-31","until":"2018-04-01","published":"2018-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 171,797,000,000 United States dollar\", as of 2017-12-31 (until 2018-04-01). Claim clm_EE41DAB95A4E, https://asof.is/claim/clm_EE41DAB95A4E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000027/0000078003-18-000027-index.htm.","url":"https://asof.is/claim/clm_EE41DAB95A4E","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"171,797,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EE41DAB95A4E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2017, filed 2018-02-22"}},{"date":"2018-02-20","until":"2018-05-07","published":"2018-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,952,864,751 shares\", as of 2018-02-20 (until 2018-05-07). Claim clm_0CB6E2E1D088, https://asof.is/claim/clm_0CB6E2E1D088, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000027/0000078003-18-000027-index.htm.","url":"https://asof.is/claim/clm_0CB6E2E1D088","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,952,864,751 shares","status":"superseded","assertable":true,"id":"clm_0CB6E2E1D088","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2017, filed 2018-02-22"}},{"date":"2018-04-01","until":"2018-07-01","published":"2018-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 70,184,000,000 United States dollar\", as of 2018-04-01 (until 2018-07-01). Claim clm_586F0445C68C, https://asof.is/claim/clm_586F0445C68C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000045/0000078003-18-000045-index.htm.","url":"https://asof.is/claim/clm_586F0445C68C","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"70,184,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_586F0445C68C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2018, filed 2018-05-10"}},{"date":"2018-04-01","until":"2018-07-01","published":"2019-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 12,906,000,000 United States dollar\", as of 2018-04-01 (until 2018-07-01). Claim clm_93302DB1670E, https://asof.is/claim/clm_93302DB1670E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000026/0000078003-19-000026-index.htm.","url":"https://asof.is/claim/clm_93302DB1670E","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"12,906,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_93302DB1670E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2019, filed 2019-05-09"}},{"date":"2018-04-01","until":"2018-07-01","published":"2018-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 3,561,000,000 United States dollar\", as of 2018-04-01 (until 2018-07-01). Claim clm_AFA166CB19E2, https://asof.is/claim/clm_AFA166CB19E2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000045/0000078003-18-000045-index.htm.","url":"https://asof.is/claim/clm_AFA166CB19E2","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"3,561,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AFA166CB19E2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2018, filed 2018-05-10"}},{"date":"2018-04-01","until":"2018-07-01","published":"2018-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 164,612,000,000 United States dollar\", as of 2018-04-01 (until 2018-07-01). Claim clm_EF01AEFD875F, https://asof.is/claim/clm_EF01AEFD875F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000045/0000078003-18-000045-index.htm.","url":"https://asof.is/claim/clm_EF01AEFD875F","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"164,612,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EF01AEFD875F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2018, filed 2018-05-10"}},{"date":"2018-04-01","until":"2018-07-01","published":"2018-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,302,000,000 United States dollar\", as of 2018-04-01 (until 2018-07-01). Claim clm_FD4466ED04A0, https://asof.is/claim/clm_FD4466ED04A0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000045/0000078003-18-000045-index.htm.","url":"https://asof.is/claim/clm_FD4466ED04A0","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,302,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FD4466ED04A0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2018, filed 2018-05-10"}},{"date":"2018-05-07","until":"2018-08-06","published":"2018-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,849,571,048 shares\", as of 2018-05-07 (until 2018-08-06). Claim clm_0421D52E73E4, https://asof.is/claim/clm_0421D52E73E4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000045/0000078003-18-000045-index.htm.","url":"https://asof.is/claim/clm_0421D52E73E4","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,849,571,048 shares","status":"superseded","assertable":true,"id":"clm_0421D52E73E4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2018, filed 2018-05-10"}},{"date":"2018-07-01","until":"2018-09-30","published":"2018-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 13,466,000,000 United States dollar\", as of 2018-07-01 (until 2018-09-30). Claim clm_3C4862C01E8A, https://asof.is/claim/clm_3C4862C01E8A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000070/0000078003-18-000070-index.htm.","url":"https://asof.is/claim/clm_3C4862C01E8A","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"13,466,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3C4862C01E8A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2018, filed 2018-08-09"}},{"date":"2018-07-01","until":"2018-09-30","published":"2018-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 164,980,000,000 United States dollar\", as of 2018-07-01 (until 2018-09-30). Claim clm_66AB7A3F250C, https://asof.is/claim/clm_66AB7A3F250C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000070/0000078003-18-000070-index.htm.","url":"https://asof.is/claim/clm_66AB7A3F250C","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"164,980,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_66AB7A3F250C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2018, filed 2018-08-09"}},{"date":"2018-07-01","until":"2018-09-30","published":"2018-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 3,872,000,000 United States dollar\", as of 2018-07-01 (until 2018-09-30). Claim clm_6E0CC2EA1334, https://asof.is/claim/clm_6E0CC2EA1334, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000070/0000078003-18-000070-index.htm.","url":"https://asof.is/claim/clm_6E0CC2EA1334","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"3,872,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6E0CC2EA1334","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2018, filed 2018-08-09"}},{"date":"2018-07-01","until":"2018-09-30","published":"2018-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,704,000,000 United States dollar\", as of 2018-07-01 (until 2018-09-30). Claim clm_7FCAD404E2AB, https://asof.is/claim/clm_7FCAD404E2AB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000070/0000078003-18-000070-index.htm.","url":"https://asof.is/claim/clm_7FCAD404E2AB","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,704,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7FCAD404E2AB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2018, filed 2018-08-09"}},{"date":"2018-07-01","until":"2018-09-30","published":"2018-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 69,778,000,000 United States dollar\", as of 2018-07-01 (until 2018-09-30). Claim clm_FE5D7E2D1CFF, https://asof.is/claim/clm_FE5D7E2D1CFF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000070/0000078003-18-000070-index.htm.","url":"https://asof.is/claim/clm_FE5D7E2D1CFF","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"69,778,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FE5D7E2D1CFF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2018, filed 2018-08-09"}},{"date":"2018-08-06","until":"2018-11-05","published":"2018-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,862,109,503 shares\", as of 2018-08-06 (until 2018-11-05). Claim clm_0DB759BE89BE, https://asof.is/claim/clm_0DB759BE89BE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000070/0000078003-18-000070-index.htm.","url":"https://asof.is/claim/clm_0DB759BE89BE","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,862,109,503 shares","status":"superseded","assertable":true,"id":"clm_0DB759BE89BE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2018, filed 2018-08-09"}},{"date":"2018-09-30","until":"2019-03-31","published":"2018-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 4,114,000,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_5FBAA553F49F, https://asof.is/claim/clm_5FBAA553F49F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000091/0000078003-18-000091-index.htm.","url":"https://asof.is/claim/clm_5FBAA553F49F","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"4,114,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5FBAA553F49F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2018, filed 2018-11-08"}},{"date":"2018-09-30","until":"2018-12-31","published":"2018-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 71,319,000,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_977F9FBD1ED5, https://asof.is/claim/clm_977F9FBD1ED5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000091/0000078003-18-000091-index.htm.","url":"https://asof.is/claim/clm_977F9FBD1ED5","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"71,319,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_977F9FBD1ED5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2018, filed 2018-11-08"}},{"date":"2018-09-30","until":"2018-12-31","published":"2018-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 167,838,000,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_9DEAAC9438BD, https://asof.is/claim/clm_9DEAAC9438BD, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000091/0000078003-18-000091-index.htm.","url":"https://asof.is/claim/clm_9DEAAC9438BD","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"167,838,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9DEAAC9438BD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2018, filed 2018-11-08"}},{"date":"2018-09-30","until":"2018-12-31","published":"2018-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 3,559,000,000 United States dollar\", as of 2018-09-30 (until 2018-12-31). Claim clm_F3F860FF7716, https://asof.is/claim/clm_F3F860FF7716, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000091/0000078003-18-000091-index.htm.","url":"https://asof.is/claim/clm_F3F860FF7716","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"3,559,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F3F860FF7716","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2018, filed 2018-11-08"}},{"date":"2018-09-30","until":"2019-03-31","published":"2018-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 13,298,000,000 United States dollar\", as of 2018-09-30 (until 2019-03-31). Claim clm_FE067F51D4DB, https://asof.is/claim/clm_FE067F51D4DB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000091/0000078003-18-000091-index.htm.","url":"https://asof.is/claim/clm_FE067F51D4DB","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"13,298,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FE067F51D4DB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2018, filed 2018-11-08"}},{"date":"2018-11-05","until":"2019-02-26","published":"2018-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,780,474,578 shares\", as of 2018-11-05 (until 2019-02-26). Claim clm_41653AD725CF, https://asof.is/claim/clm_41653AD725CF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800318000091/0000078003-18-000091-index.htm.","url":"https://asof.is/claim/clm_41653AD725CF","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,780,474,578 shares","status":"superseded","assertable":true,"id":"clm_41653AD725CF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2018, filed 2018-11-08"}},{"date":"2018-12-31","until":"2019-12-31","published":"2019-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer revenue: 53,647,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_052E7C8C40A7, https://asof.is/claim/clm_052E7C8C40A7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000015/0000078003-19-000015-index.htm.","url":"https://asof.is/claim/clm_052E7C8C40A7","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"53,647,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_052E7C8C40A7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2018, filed 2019-02-28"}},{"date":"2018-12-31","until":"2019-03-31","published":"2019-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 63,407,000,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_6C92A8E3F7CA, https://asof.is/claim/clm_6C92A8E3F7CA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000015/0000078003-19-000015-index.htm.","url":"https://asof.is/claim/clm_6C92A8E3F7CA","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"63,407,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6C92A8E3F7CA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2018, filed 2019-02-28"}},{"date":"2018-12-31","until":"2019-03-31","published":"2019-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 159,422,000,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_71E7F8BDBA7F, https://asof.is/claim/clm_71E7F8BDBA7F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000015/0000078003-19-000015-index.htm.","url":"https://asof.is/claim/clm_71E7F8BDBA7F","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"159,422,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_71E7F8BDBA7F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2018, filed 2019-02-28"}},{"date":"2018-12-31","until":"2019-03-31","published":"2019-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,139,000,000 United States dollar\", as of 2018-12-31 (until 2019-03-31). Claim clm_CD28817DB057, https://asof.is/claim/clm_CD28817DB057, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000015/0000078003-19-000015-index.htm.","url":"https://asof.is/claim/clm_CD28817DB057","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,139,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CD28817DB057","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2018, filed 2019-02-28"}},{"date":"2018-12-31","until":"2019-12-31","published":"2019-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 11,153,000,000 United States dollar\", as of 2018-12-31 (until 2019-12-31). Claim clm_E82040CDE79A, https://asof.is/claim/clm_E82040CDE79A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000015/0000078003-19-000015-index.htm.","url":"https://asof.is/claim/clm_E82040CDE79A","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"11,153,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E82040CDE79A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2018, filed 2019-02-28"}},{"date":"2019-02-26","until":"2019-05-06","published":"2019-02-28","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,551,804,790 shares\", as of 2019-02-26 (until 2019-05-06). Claim clm_478AA8D1FB13, https://asof.is/claim/clm_478AA8D1FB13, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000015/0000078003-19-000015-index.htm.","url":"https://asof.is/claim/clm_478AA8D1FB13","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,551,804,790 shares","status":"superseded","assertable":true,"id":"clm_478AA8D1FB13","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2018, filed 2019-02-28"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 13,118,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_1E39DDDC01E7, https://asof.is/claim/clm_1E39DDDC01E7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000026/0000078003-19-000026-index.htm.","url":"https://asof.is/claim/clm_1E39DDDC01E7","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"13,118,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1E39DDDC01E7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2019, filed 2019-05-09"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,937,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_5499517987EE, https://asof.is/claim/clm_5499517987EE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000026/0000078003-19-000026-index.htm.","url":"https://asof.is/claim/clm_5499517987EE","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,937,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5499517987EE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2019, filed 2019-05-09"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 155,421,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_7EB4AB9AD065, https://asof.is/claim/clm_7EB4AB9AD065, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000026/0000078003-19-000026-index.htm.","url":"https://asof.is/claim/clm_7EB4AB9AD065","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"155,421,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7EB4AB9AD065","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2019, filed 2019-05-09"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 3,884,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_94879C1CC409, https://asof.is/claim/clm_94879C1CC409, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000026/0000078003-19-000026-index.htm.","url":"https://asof.is/claim/clm_94879C1CC409","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"3,884,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_94879C1CC409","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2019, filed 2019-05-09"}},{"date":"2019-03-31","until":"2019-06-30","published":"2019-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 58,806,000,000 United States dollar\", as of 2019-03-31 (until 2019-06-30). Claim clm_99670AF4983A, https://asof.is/claim/clm_99670AF4983A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000026/0000078003-19-000026-index.htm.","url":"https://asof.is/claim/clm_99670AF4983A","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"58,806,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_99670AF4983A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2019, filed 2019-05-09"}},{"date":"2019-05-06","until":"2019-08-05","published":"2019-05-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,559,929,190 shares\", as of 2019-05-06 (until 2019-08-05). Claim clm_1006A3A1960D, https://asof.is/claim/clm_1006A3A1960D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000026/0000078003-19-000026-index.htm.","url":"https://asof.is/claim/clm_1006A3A1960D","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,559,929,190 shares","status":"superseded","assertable":true,"id":"clm_1006A3A1960D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2019, filed 2019-05-09"}},{"date":"2019-06-30","until":"2019-09-29","published":"2019-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 59,568,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-29). Claim clm_0220898E70A4, https://asof.is/claim/clm_0220898E70A4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000064/0000078003-19-000064-index.htm.","url":"https://asof.is/claim/clm_0220898E70A4","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"59,568,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0220898E70A4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2019, filed 2019-08-08"}},{"date":"2019-06-30","until":"2019-09-29","published":"2019-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,784,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-29). Claim clm_2A748F757318, https://asof.is/claim/clm_2A748F757318, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000064/0000078003-19-000064-index.htm.","url":"https://asof.is/claim/clm_2A748F757318","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,784,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2A748F757318","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2019, filed 2019-08-08"}},{"date":"2019-06-30","until":"2019-09-29","published":"2019-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 156,199,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-29). Claim clm_6E7BC2D8FC44, https://asof.is/claim/clm_6E7BC2D8FC44, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000064/0000078003-19-000064-index.htm.","url":"https://asof.is/claim/clm_6E7BC2D8FC44","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"156,199,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6E7BC2D8FC44","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2019, filed 2019-08-08"}},{"date":"2019-06-30","until":"2019-09-29","published":"2019-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 5,046,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-29). Claim clm_97D4E10E1F45, https://asof.is/claim/clm_97D4E10E1F45, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000064/0000078003-19-000064-index.htm.","url":"https://asof.is/claim/clm_97D4E10E1F45","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"5,046,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_97D4E10E1F45","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2019, filed 2019-08-08"}},{"date":"2019-06-30","until":"2019-09-29","published":"2019-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 13,264,000,000 United States dollar\", as of 2019-06-30 (until 2019-09-29). Claim clm_CF98952D6203, https://asof.is/claim/clm_CF98952D6203, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000064/0000078003-19-000064-index.htm.","url":"https://asof.is/claim/clm_CF98952D6203","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"13,264,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CF98952D6203","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2019, filed 2019-08-08"}},{"date":"2019-08-05","until":"2019-11-04","published":"2019-08-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,531,048,353 shares\", as of 2019-08-05 (until 2019-11-04). Claim clm_94D6A2BDF7C9, https://asof.is/claim/clm_94D6A2BDF7C9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000064/0000078003-19-000064-index.htm.","url":"https://asof.is/claim/clm_94D6A2BDF7C9","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,531,048,353 shares","status":"superseded","assertable":true,"id":"clm_94D6A2BDF7C9","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2019, filed 2019-08-08"}},{"date":"2019-09-29","until":"2019-12-31","published":"2019-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 65,103,000,000 United States dollar\", as of 2019-09-29 (until 2019-12-31). Claim clm_0F365D02E067, https://asof.is/claim/clm_0F365D02E067, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000082/0000078003-19-000082-index.htm.","url":"https://asof.is/claim/clm_0F365D02E067","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"65,103,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0F365D02E067","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2019, filed 2019-11-07"}},{"date":"2019-09-29","until":"2020-03-29","published":"2019-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 12,680,000,000 United States dollar\", as of 2019-09-29 (until 2020-03-29). Claim clm_889C767A67EA, https://asof.is/claim/clm_889C767A67EA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000082/0000078003-19-000082-index.htm.","url":"https://asof.is/claim/clm_889C767A67EA","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"12,680,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_889C767A67EA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2019, filed 2019-11-07"}},{"date":"2019-09-29","until":"2019-12-31","published":"2019-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,785,000,000 United States dollar\", as of 2019-09-29 (until 2019-12-31). Claim clm_9CC505F86CEA, https://asof.is/claim/clm_9CC505F86CEA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000082/0000078003-19-000082-index.htm.","url":"https://asof.is/claim/clm_9CC505F86CEA","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,785,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9CC505F86CEA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2019, filed 2019-11-07"}},{"date":"2019-09-29","until":"2020-03-29","published":"2019-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 7,680,000,000 United States dollar\", as of 2019-09-29 (until 2020-03-29). Claim clm_C432921CA049, https://asof.is/claim/clm_C432921CA049, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000082/0000078003-19-000082-index.htm.","url":"https://asof.is/claim/clm_C432921CA049","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"7,680,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C432921CA049","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2019, filed 2019-11-07"}},{"date":"2019-09-29","until":"2019-12-31","published":"2019-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 170,446,000,000 United States dollar\", as of 2019-09-29 (until 2019-12-31). Claim clm_DF5A42032239, https://asof.is/claim/clm_DF5A42032239, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000082/0000078003-19-000082-index.htm.","url":"https://asof.is/claim/clm_DF5A42032239","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"170,446,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DF5A42032239","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2019, filed 2019-11-07"}},{"date":"2019-11-04","until":"2020-02-25","published":"2019-11-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,534,122,364 shares\", as of 2019-11-04 (until 2020-02-25). Claim clm_73071508C237, https://asof.is/claim/clm_73071508C237, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800319000082/0000078003-19-000082-index.htm.","url":"https://asof.is/claim/clm_73071508C237","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,534,122,364 shares","status":"superseded","assertable":true,"id":"clm_73071508C237","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2019, filed 2019-11-07"}},{"date":"2019-12-31","until":"2020-12-31","published":"2020-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer revenue: 51,750,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_39A482B707D0, https://asof.is/claim/clm_39A482B707D0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000014/0000078003-20-000014-index.htm.","url":"https://asof.is/claim/clm_39A482B707D0","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"51,750,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_39A482B707D0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2019, filed 2020-02-27"}},{"date":"2019-12-31","until":"2020-03-29","published":"2020-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 63,143,000,000 United States dollar\", as of 2019-12-31 (until 2020-03-29). Claim clm_57D82271BA05, https://asof.is/claim/clm_57D82271BA05, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000014/0000078003-20-000014-index.htm.","url":"https://asof.is/claim/clm_57D82271BA05","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"63,143,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_57D82271BA05","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2019, filed 2020-02-27"}},{"date":"2019-12-31","until":"2020-03-29","published":"2020-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,305,000,000 United States dollar\", as of 2019-12-31 (until 2020-03-29). Claim clm_7EB2CF895C11, https://asof.is/claim/clm_7EB2CF895C11, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000014/0000078003-20-000014-index.htm.","url":"https://asof.is/claim/clm_7EB2CF895C11","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,305,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7EB2CF895C11","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2019, filed 2020-02-27"}},{"date":"2019-12-31","until":"2020-03-29","published":"2020-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 167,489,000,000 United States dollar\", as of 2019-12-31 (until 2020-03-29). Claim clm_A8CF8D70D497, https://asof.is/claim/clm_A8CF8D70D497, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000014/0000078003-20-000014-index.htm.","url":"https://asof.is/claim/clm_A8CF8D70D497","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"167,489,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A8CF8D70D497","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2019, filed 2020-02-27"}},{"date":"2019-12-31","until":"2020-12-31","published":"2020-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 16,273,000,000 United States dollar\", as of 2019-12-31 (until 2020-12-31). Claim clm_E9122BFE1E6C, https://asof.is/claim/clm_E9122BFE1E6C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000014/0000078003-20-000014-index.htm.","url":"https://asof.is/claim/clm_E9122BFE1E6C","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"16,273,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E9122BFE1E6C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2019, filed 2020-02-27"}},{"date":"2020-02-25","until":"2020-05-04","published":"2020-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,547,639,005 shares\", as of 2020-02-25 (until 2020-05-04). Claim clm_E3F80D154DF3, https://asof.is/claim/clm_E3F80D154DF3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000014/0000078003-20-000014-index.htm.","url":"https://asof.is/claim/clm_E3F80D154DF3","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,547,639,005 shares","status":"superseded","assertable":true,"id":"clm_E3F80D154DF3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2019, filed 2020-02-27"}},{"date":"2020-03-29","until":"2020-06-28","published":"2020-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 166,336,000,000 United States dollar\", as of 2020-03-29 (until 2020-06-28). Claim clm_6039ACB538EA, https://asof.is/claim/clm_6039ACB538EA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000037/0000078003-20-000037-index.htm.","url":"https://asof.is/claim/clm_6039ACB538EA","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"166,336,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6039ACB538EA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2020, filed 2020-05-07"}},{"date":"2020-03-29","until":"2020-06-28","published":"2020-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 12,028,000,000 United States dollar\", as of 2020-03-29 (until 2020-06-28). Claim clm_78A6A26A31D2, https://asof.is/claim/clm_78A6A26A31D2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000037/0000078003-20-000037-index.htm.","url":"https://asof.is/claim/clm_78A6A26A31D2","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"12,028,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_78A6A26A31D2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2020, filed 2020-05-07"}},{"date":"2020-03-29","until":"2020-06-28","published":"2020-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,151,000,000 United States dollar\", as of 2020-03-29 (until 2020-06-28). Claim clm_7EC574F3CF88, https://asof.is/claim/clm_7EC574F3CF88, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000037/0000078003-20-000037-index.htm.","url":"https://asof.is/claim/clm_7EC574F3CF88","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,151,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7EC574F3CF88","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2020, filed 2020-05-07"}},{"date":"2020-03-29","until":"2020-06-28","published":"2020-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 3,401,000,000 United States dollar\", as of 2020-03-29 (until 2020-06-28). Claim clm_C58A9E807DA2, https://asof.is/claim/clm_C58A9E807DA2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000037/0000078003-20-000037-index.htm.","url":"https://asof.is/claim/clm_C58A9E807DA2","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"3,401,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C58A9E807DA2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2020, filed 2020-05-07"}},{"date":"2020-03-29","until":"2020-06-28","published":"2020-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 65,026,000,000 United States dollar\", as of 2020-03-29 (until 2020-06-28). Claim clm_DC08B9403A6A, https://asof.is/claim/clm_DC08B9403A6A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000037/0000078003-20-000037-index.htm.","url":"https://asof.is/claim/clm_DC08B9403A6A","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"65,026,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DC08B9403A6A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2020, filed 2020-05-07"}},{"date":"2020-05-04","until":"2020-08-03","published":"2020-05-07","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,554,833,754 shares\", as of 2020-05-04 (until 2020-08-03). Claim clm_C2EFDB961A99, https://asof.is/claim/clm_C2EFDB961A99, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000037/0000078003-20-000037-index.htm.","url":"https://asof.is/claim/clm_C2EFDB961A99","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,554,833,754 shares","status":"superseded","assertable":true,"id":"clm_C2EFDB961A99","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2020, filed 2020-05-07"}},{"date":"2020-06-28","until":"2020-09-27","published":"2020-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,801,000,000 United States dollar\", as of 2020-06-28 (until 2020-09-27). Claim clm_1D3141B3D8BE, https://asof.is/claim/clm_1D3141B3D8BE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000060/0000078003-20-000060-index.htm.","url":"https://asof.is/claim/clm_1D3141B3D8BE","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,801,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1D3141B3D8BE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2020, filed 2020-08-06"}},{"date":"2020-06-28","until":"2020-09-27","published":"2020-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 64,336,000,000 United States dollar\", as of 2020-06-28 (until 2020-09-27). Claim clm_5297D5930968, https://asof.is/claim/clm_5297D5930968, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000060/0000078003-20-000060-index.htm.","url":"https://asof.is/claim/clm_5297D5930968","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"64,336,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5297D5930968","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2020, filed 2020-08-06"}},{"date":"2020-06-28","until":"2020-09-27","published":"2020-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 3,426,000,000 United States dollar\", as of 2020-06-28 (until 2020-09-27). Claim clm_7B12C5323F06, https://asof.is/claim/clm_7B12C5323F06, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000060/0000078003-20-000060-index.htm.","url":"https://asof.is/claim/clm_7B12C5323F06","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"3,426,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7B12C5323F06","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2020, filed 2020-08-06"}},{"date":"2020-06-28","until":"2020-09-27","published":"2020-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 11,801,000,000 United States dollar\", as of 2020-06-28 (until 2020-09-27). Claim clm_B1CB42C2F7EF, https://asof.is/claim/clm_B1CB42C2F7EF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000060/0000078003-20-000060-index.htm.","url":"https://asof.is/claim/clm_B1CB42C2F7EF","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"11,801,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B1CB42C2F7EF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2020, filed 2020-08-06"}},{"date":"2020-06-28","until":"2020-09-27","published":"2020-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 177,934,000,000 United States dollar\", as of 2020-06-28 (until 2020-09-27). Claim clm_F3731FFF05AB, https://asof.is/claim/clm_F3731FFF05AB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000060/0000078003-20-000060-index.htm.","url":"https://asof.is/claim/clm_F3731FFF05AB","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"177,934,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F3731FFF05AB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2020, filed 2020-08-06"}},{"date":"2020-08-03","until":"2020-11-02","published":"2020-08-06","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,556,879,807 shares\", as of 2020-08-03 (until 2020-11-02). Claim clm_E266190C8665, https://asof.is/claim/clm_E266190C8665, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000060/0000078003-20-000060-index.htm.","url":"https://asof.is/claim/clm_E266190C8665","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,556,879,807 shares","status":"superseded","assertable":true,"id":"clm_E266190C8665","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2020, filed 2020-08-06"}},{"date":"2020-09-27","until":"2020-12-31","published":"2020-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,587,000,000 United States dollar\", as of 2020-09-27 (until 2020-12-31). Claim clm_0F021947D590, https://asof.is/claim/clm_0F021947D590, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000070/0000078003-20-000070-index.htm.","url":"https://asof.is/claim/clm_0F021947D590","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,587,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0F021947D590","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2020, filed 2020-11-05"}},{"date":"2020-09-27","until":"2020-12-31","published":"2020-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 178,983,000,000 United States dollar\", as of 2020-09-27 (until 2020-12-31). Claim clm_598B51876590, https://asof.is/claim/clm_598B51876590, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000070/0000078003-20-000070-index.htm.","url":"https://asof.is/claim/clm_598B51876590","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"178,983,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_598B51876590","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2020, filed 2020-11-05"}},{"date":"2020-09-27","until":"2020-12-31","published":"2020-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 65,259,000,000 United States dollar\", as of 2020-09-27 (until 2020-12-31). Claim clm_A40D02FA0190, https://asof.is/claim/clm_A40D02FA0190, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000070/0000078003-20-000070-index.htm.","url":"https://asof.is/claim/clm_A40D02FA0190","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"65,259,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A40D02FA0190","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2020, filed 2020-11-05"}},{"date":"2020-09-27","until":"2021-04-04","published":"2020-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 12,131,000,000 United States dollar\", as of 2020-09-27 (until 2021-04-04). Claim clm_C2761A47BD4C, https://asof.is/claim/clm_C2761A47BD4C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000070/0000078003-20-000070-index.htm.","url":"https://asof.is/claim/clm_C2761A47BD4C","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"12,131,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C2761A47BD4C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2020, filed 2020-11-05"}},{"date":"2020-09-27","until":"2021-04-04","published":"2020-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,194,000,000 United States dollar\", as of 2020-09-27 (until 2021-04-04). Claim clm_C93A3C9ACE17, https://asof.is/claim/clm_C93A3C9ACE17, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000070/0000078003-20-000070-index.htm.","url":"https://asof.is/claim/clm_C93A3C9ACE17","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,194,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C93A3C9ACE17","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2020, filed 2020-11-05"}},{"date":"2020-11-02","until":"2021-02-23","published":"2020-11-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,558,396,599 shares\", as of 2020-11-02 (until 2021-02-23). Claim clm_F72DAF7CFE35, https://asof.is/claim/clm_F72DAF7CFE35, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800320000070/0000078003-20-000070-index.htm.","url":"https://asof.is/claim/clm_F72DAF7CFE35","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,558,396,599 shares","status":"superseded","assertable":true,"id":"clm_F72DAF7CFE35","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2020, filed 2020-11-05"}},{"date":"2020-12-31","until":"2021-04-04","published":"2021-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,784,000,000 United States dollar\", as of 2020-12-31 (until 2021-04-04). Claim clm_13E996AD9BD6, https://asof.is/claim/clm_13E996AD9BD6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000038/0000078003-21-000038-index.htm.","url":"https://asof.is/claim/clm_13E996AD9BD6","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,784,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_13E996AD9BD6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2020, filed 2021-02-25"}},{"date":"2020-12-31","until":"2021-04-04","published":"2021-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 154,229,000,000 United States dollar\", as of 2020-12-31 (until 2021-04-04). Claim clm_22B92DB79DB2, https://asof.is/claim/clm_22B92DB79DB2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000038/0000078003-21-000038-index.htm.","url":"https://asof.is/claim/clm_22B92DB79DB2","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"154,229,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_22B92DB79DB2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2020, filed 2021-02-25"}},{"date":"2020-12-31","until":"2021-04-04","published":"2021-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 63,238,000,000 United States dollar\", as of 2020-12-31 (until 2021-04-04). Claim clm_464EC8256E1D, https://asof.is/claim/clm_464EC8256E1D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000038/0000078003-21-000038-index.htm.","url":"https://asof.is/claim/clm_464EC8256E1D","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"63,238,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_464EC8256E1D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2020, filed 2021-02-25"}},{"date":"2020-12-31","until":"2021-12-31","published":"2021-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 9,616,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_A0FD17F0B861, https://asof.is/claim/clm_A0FD17F0B861, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000038/0000078003-21-000038-index.htm.","url":"https://asof.is/claim/clm_A0FD17F0B861","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"9,616,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A0FD17F0B861","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2020, filed 2021-02-25"}},{"date":"2020-12-31","until":"2021-12-31","published":"2023-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer revenue: 41,651,000,000 United States dollar\", as of 2020-12-31 (until 2021-12-31). Claim clm_E33934BCDEB6, https://asof.is/claim/clm_E33934BCDEB6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000024/0000078003-23-000024-index.htm.","url":"https://asof.is/claim/clm_E33934BCDEB6","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"41,651,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E33934BCDEB6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2022, filed 2023-02-23"}},{"date":"2021-02-23","until":"2021-05-10","published":"2021-02-25","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,577,629,491 shares\", as of 2021-02-23 (until 2021-05-10). Claim clm_3D205C52B671, https://asof.is/claim/clm_3D205C52B671, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000038/0000078003-21-000038-index.htm.","url":"https://asof.is/claim/clm_3D205C52B671","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,577,629,491 shares","status":"superseded","assertable":true,"id":"clm_3D205C52B671","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2020, filed 2021-02-25"}},{"date":"2021-04-04","until":"2021-07-04","published":"2021-05-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 14,582,000,000 United States dollar\", as of 2021-04-04 (until 2021-07-04). Claim clm_4BE15DDF3498, https://asof.is/claim/clm_4BE15DDF3498, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000065/0000078003-21-000065-index.htm.","url":"https://asof.is/claim/clm_4BE15DDF3498","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"14,582,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4BE15DDF3498","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q1 FY2021, filed 2021-05-13"}},{"date":"2021-04-04","until":"2021-07-04","published":"2021-05-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,768,000,000 United States dollar\", as of 2021-04-04 (until 2021-07-04). Claim clm_591B44157720, https://asof.is/claim/clm_591B44157720, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000065/0000078003-21-000065-index.htm.","url":"https://asof.is/claim/clm_591B44157720","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,768,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_591B44157720","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2021, filed 2021-05-13"}},{"date":"2021-04-04","until":"2021-07-04","published":"2021-05-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 158,818,000,000 United States dollar\", as of 2021-04-04 (until 2021-07-04). Claim clm_6AAA95B0FE7B, https://asof.is/claim/clm_6AAA95B0FE7B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000065/0000078003-21-000065-index.htm.","url":"https://asof.is/claim/clm_6AAA95B0FE7B","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"158,818,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6AAA95B0FE7B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2021, filed 2021-05-13"}},{"date":"2021-04-04","until":"2021-07-04","published":"2021-05-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 4,877,000,000 United States dollar\", as of 2021-04-04 (until 2021-07-04). Claim clm_6EEB2DC7425B, https://asof.is/claim/clm_6EEB2DC7425B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000065/0000078003-21-000065-index.htm.","url":"https://asof.is/claim/clm_6EEB2DC7425B","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"4,877,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6EEB2DC7425B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2021, filed 2021-05-13"}},{"date":"2021-04-04","until":"2021-07-04","published":"2021-05-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 68,620,000,000 United States dollar\", as of 2021-04-04 (until 2021-07-04). Claim clm_D7FD7922934D, https://asof.is/claim/clm_D7FD7922934D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000065/0000078003-21-000065-index.htm.","url":"https://asof.is/claim/clm_D7FD7922934D","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"68,620,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D7FD7922934D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2021, filed 2021-05-13"}},{"date":"2021-05-10","until":"2021-08-09","published":"2021-05-13","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,597,693,867 shares\", as of 2021-05-10 (until 2021-08-09). Claim clm_25AD8F550E87, https://asof.is/claim/clm_25AD8F550E87, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000065/0000078003-21-000065-index.htm.","url":"https://asof.is/claim/clm_25AD8F550E87","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,597,693,867 shares","status":"superseded","assertable":true,"id":"clm_25AD8F550E87","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2021, filed 2021-05-13"}},{"date":"2021-07-04","until":"2021-10-03","published":"2021-08-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 169,920,000,000 United States dollar\", as of 2021-07-04 (until 2021-10-03). Claim clm_18BCAA4CD478, https://asof.is/claim/clm_18BCAA4CD478, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000093/0000078003-21-000093-index.htm.","url":"https://asof.is/claim/clm_18BCAA4CD478","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"169,920,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_18BCAA4CD478","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2021, filed 2021-08-12"}},{"date":"2021-07-04","until":"2021-10-03","published":"2021-08-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 70,042,000,000 United States dollar\", as of 2021-07-04 (until 2021-10-03). Claim clm_57353E97AECD, https://asof.is/claim/clm_57353E97AECD, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000093/0000078003-21-000093-index.htm.","url":"https://asof.is/claim/clm_57353E97AECD","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"70,042,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_57353E97AECD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2021, filed 2021-08-12"}},{"date":"2021-07-04","until":"2021-10-03","published":"2021-08-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 5,563,000,000 United States dollar\", as of 2021-07-04 (until 2021-10-03). Claim clm_6EAE6253723D, https://asof.is/claim/clm_6EAE6253723D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000093/0000078003-21-000093-index.htm.","url":"https://asof.is/claim/clm_6EAE6253723D","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"5,563,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6EAE6253723D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2021, filed 2021-08-12"}},{"date":"2021-07-04","until":"2021-10-03","published":"2021-08-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,372,000,000 United States dollar\", as of 2021-07-04 (until 2021-10-03). Claim clm_8E302236F0B5, https://asof.is/claim/clm_8E302236F0B5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000093/0000078003-21-000093-index.htm.","url":"https://asof.is/claim/clm_8E302236F0B5","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,372,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8E302236F0B5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2021, filed 2021-08-12"}},{"date":"2021-07-04","until":"2021-10-03","published":"2021-08-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 18,977,000,000 United States dollar\", as of 2021-07-04 (until 2021-10-03). Claim clm_A86BA19D0AEC, https://asof.is/claim/clm_A86BA19D0AEC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000093/0000078003-21-000093-index.htm.","url":"https://asof.is/claim/clm_A86BA19D0AEC","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"18,977,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A86BA19D0AEC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q2 FY2021, filed 2021-08-12"}},{"date":"2021-08-09","until":"2021-11-08","published":"2021-08-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,606,688,356 shares\", as of 2021-08-09 (until 2021-11-08). Claim clm_F13B391E1DBB, https://asof.is/claim/clm_F13B391E1DBB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000093/0000078003-21-000093-index.htm.","url":"https://asof.is/claim/clm_F13B391E1DBB","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,606,688,356 shares","status":"superseded","assertable":true,"id":"clm_F13B391E1DBB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2021, filed 2021-08-12"}},{"date":"2021-10-03","until":"2022-04-03","published":"2021-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 24,094,000,000 United States dollar\", as of 2021-10-03 (until 2022-04-03). Claim clm_2211869D267D, https://asof.is/claim/clm_2211869D267D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000107/0000078003-21-000107-index.htm.","url":"https://asof.is/claim/clm_2211869D267D","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"24,094,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2211869D267D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2021, filed 2021-11-12"}},{"date":"2021-10-03","until":"2021-12-31","published":"2021-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,966,000,000 United States dollar\", as of 2021-10-03 (until 2021-12-31). Claim clm_5142AD1CFC09, https://asof.is/claim/clm_5142AD1CFC09, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000107/0000078003-21-000107-index.htm.","url":"https://asof.is/claim/clm_5142AD1CFC09","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,966,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5142AD1CFC09","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2021, filed 2021-11-12"}},{"date":"2021-10-03","until":"2021-12-31","published":"2021-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 179,188,000,000 United States dollar\", as of 2021-10-03 (until 2021-12-31). Claim clm_A78436F424CA, https://asof.is/claim/clm_A78436F424CA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000107/0000078003-21-000107-index.htm.","url":"https://asof.is/claim/clm_A78436F424CA","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"179,188,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A78436F424CA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2021, filed 2021-11-12"}},{"date":"2021-10-03","until":"2021-12-31","published":"2021-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 75,691,000,000 United States dollar\", as of 2021-10-03 (until 2021-12-31). Claim clm_B6622300AB98, https://asof.is/claim/clm_B6622300AB98, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000107/0000078003-21-000107-index.htm.","url":"https://asof.is/claim/clm_B6622300AB98","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"75,691,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B6622300AB98","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2021, filed 2021-11-12"}},{"date":"2021-10-03","until":"2022-04-03","published":"2021-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 8,146,000,000 United States dollar\", as of 2021-10-03 (until 2022-04-03). Claim clm_F7664122D433, https://asof.is/claim/clm_F7664122D433, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000107/0000078003-21-000107-index.htm.","url":"https://asof.is/claim/clm_F7664122D433","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"8,146,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F7664122D433","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2021, filed 2021-11-12"}},{"date":"2021-11-08","until":"2022-02-22","published":"2021-11-12","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,612,866,598 shares\", as of 2021-11-08 (until 2022-02-22). Claim clm_F3A7A466D205, https://asof.is/claim/clm_F3A7A466D205, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800321000107/0000078003-21-000107-index.htm.","url":"https://asof.is/claim/clm_F3A7A466D205","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,612,866,598 shares","status":"superseded","assertable":true,"id":"clm_F3A7A466D205","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2021, filed 2021-11-12"}},{"date":"2021-12-31","until":"2022-04-03","published":"2022-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 77,201,000,000 United States dollar\", as of 2021-12-31 (until 2022-04-03). Claim clm_45F0BC9B0BAB, https://asof.is/claim/clm_45F0BC9B0BAB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800322000027/0000078003-22-000027-index.htm.","url":"https://asof.is/claim/clm_45F0BC9B0BAB","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"77,201,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_45F0BC9B0BAB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2021, filed 2022-02-24"}},{"date":"2021-12-31","until":"2022-04-03","published":"2022-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,944,000,000 United States dollar\", as of 2021-12-31 (until 2022-04-03). Claim clm_5494D0A65D17, https://asof.is/claim/clm_5494D0A65D17, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800322000027/0000078003-22-000027-index.htm.","url":"https://asof.is/claim/clm_5494D0A65D17","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,944,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5494D0A65D17","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2021, filed 2022-02-24"}},{"date":"2021-12-31","until":"2022-12-31","published":"2022-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 21,979,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_5D4C717AB3B8, https://asof.is/claim/clm_5D4C717AB3B8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800322000027/0000078003-22-000027-index.htm.","url":"https://asof.is/claim/clm_5D4C717AB3B8","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"21,979,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5D4C717AB3B8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2021, filed 2022-02-24"}},{"date":"2021-12-31","until":"2022-04-03","published":"2022-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 181,476,000,000 United States dollar\", as of 2021-12-31 (until 2022-04-03). Claim clm_ABAAA591761C, https://asof.is/claim/clm_ABAAA591761C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800322000027/0000078003-22-000027-index.htm.","url":"https://asof.is/claim/clm_ABAAA591761C","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"181,476,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ABAAA591761C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2021, filed 2022-02-24"}},{"date":"2021-12-31","until":"2022-12-31","published":"2023-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer revenue: 81,288,000,000 United States dollar\", as of 2021-12-31 (until 2022-12-31). Claim clm_CF1DC7D31DB2, https://asof.is/claim/clm_CF1DC7D31DB2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000024/0000078003-23-000024-index.htm.","url":"https://asof.is/claim/clm_CF1DC7D31DB2","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"81,288,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CF1DC7D31DB2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2022, filed 2023-02-23"}},{"date":"2022-02-22","until":"2022-05-06","published":"2022-02-24","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,623,346,471 shares\", as of 2022-02-22 (until 2022-05-06). Claim clm_B985D002E8CA, https://asof.is/claim/clm_B985D002E8CA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800322000027/0000078003-22-000027-index.htm.","url":"https://asof.is/claim/clm_B985D002E8CA","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,623,346,471 shares","status":"superseded","assertable":true,"id":"clm_B985D002E8CA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2021, filed 2022-02-24"}},{"date":"2022-04-03","until":"2022-07-03","published":"2022-05-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 7,864,000,000 United States dollar\", as of 2022-04-03 (until 2022-07-03). Claim clm_01A86747A8D0, https://asof.is/claim/clm_01A86747A8D0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800322000071/0000078003-22-000071-index.htm.","url":"https://asof.is/claim/clm_01A86747A8D0","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"7,864,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_01A86747A8D0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2022, filed 2022-05-11"}},{"date":"2022-04-03","until":"2022-07-03","published":"2023-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 25,661,000,000 United States dollar\", as of 2022-04-03 (until 2022-07-03). Claim clm_7ED72F69640D, https://asof.is/claim/clm_7ED72F69640D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000162828023017196/0001628280-23-017196-index.htm.","url":"https://asof.is/claim/clm_7ED72F69640D","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"25,661,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7ED72F69640D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2023, filed 2023-05-10"}},{"date":"2022-04-03","until":"2022-07-03","published":"2022-05-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 183,841,000,000 United States dollar\", as of 2022-04-03 (until 2022-07-03). Claim clm_C13ACECA4F57, https://asof.is/claim/clm_C13ACECA4F57, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800322000071/0000078003-22-000071-index.htm.","url":"https://asof.is/claim/clm_C13ACECA4F57","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"183,841,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C13ACECA4F57","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2022, filed 2022-05-11"}},{"date":"2022-04-03","until":"2022-07-03","published":"2022-05-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 82,424,000,000 United States dollar\", as of 2022-04-03 (until 2022-07-03). Claim clm_CCBABDB37AE0, https://asof.is/claim/clm_CCBABDB37AE0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800322000071/0000078003-22-000071-index.htm.","url":"https://asof.is/claim/clm_CCBABDB37AE0","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"82,424,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_CCBABDB37AE0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2022, filed 2022-05-11"}},{"date":"2022-04-03","until":"2022-07-03","published":"2022-05-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,470,000,000 United States dollar\", as of 2022-04-03 (until 2022-07-03). Claim clm_E9DC797FB50C, https://asof.is/claim/clm_E9DC797FB50C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800322000071/0000078003-22-000071-index.htm.","url":"https://asof.is/claim/clm_E9DC797FB50C","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,470,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E9DC797FB50C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2022, filed 2022-05-11"}},{"date":"2022-05-06","until":"2022-08-05","published":"2022-05-11","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,610,895,801 shares\", as of 2022-05-06 (until 2022-08-05). Claim clm_5D3481835E90, https://asof.is/claim/clm_5D3481835E90, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800322000071/0000078003-22-000071-index.htm.","url":"https://asof.is/claim/clm_5D3481835E90","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,610,895,801 shares","status":"superseded","assertable":true,"id":"clm_5D3481835E90","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2022, filed 2022-05-11"}},{"date":"2022-07-03","until":"2022-10-02","published":"2023-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 27,742,000,000 United States dollar\", as of 2022-07-03 (until 2022-10-02). Claim clm_2A546CD0F3BF, https://asof.is/claim/clm_2A546CD0F3BF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000088/0000078003-23-000088-index.htm.","url":"https://asof.is/claim/clm_2A546CD0F3BF","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"27,742,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2A546CD0F3BF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2023, filed 2023-08-09"}},{"date":"2022-07-03","until":"2022-10-02","published":"2022-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 195,290,000,000 United States dollar\", as of 2022-07-03 (until 2022-10-02). Claim clm_344D9BE41DE1, https://asof.is/claim/clm_344D9BE41DE1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800322000094/0000078003-22-000094-index.htm.","url":"https://asof.is/claim/clm_344D9BE41DE1","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"195,290,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_344D9BE41DE1","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2022, filed 2022-08-10"}},{"date":"2022-07-03","until":"2022-10-02","published":"2022-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,780,000,000 United States dollar\", as of 2022-07-03 (until 2022-10-02). Claim clm_5481970B0F0A, https://asof.is/claim/clm_5481970B0F0A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800322000094/0000078003-22-000094-index.htm.","url":"https://asof.is/claim/clm_5481970B0F0A","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,780,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_5481970B0F0A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2022, filed 2022-08-10"}},{"date":"2022-07-03","until":"2022-10-02","published":"2022-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 9,906,000,000 United States dollar\", as of 2022-07-03 (until 2022-10-02). Claim clm_7FF3ED210A93, https://asof.is/claim/clm_7FF3ED210A93, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800322000094/0000078003-22-000094-index.htm.","url":"https://asof.is/claim/clm_7FF3ED210A93","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"9,906,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7FF3ED210A93","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2022, filed 2022-08-10"}},{"date":"2022-07-03","until":"2022-10-02","published":"2022-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 87,208,000,000 United States dollar\", as of 2022-07-03 (until 2022-10-02). Claim clm_BFD5497AC505, https://asof.is/claim/clm_BFD5497AC505, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800322000094/0000078003-22-000094-index.htm.","url":"https://asof.is/claim/clm_BFD5497AC505","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"87,208,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BFD5497AC505","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2022, filed 2022-08-10"}},{"date":"2022-08-05","until":"2022-11-04","published":"2022-08-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,612,351,809 shares\", as of 2022-08-05 (until 2022-11-04). Claim clm_22CDDDACC93C, https://asof.is/claim/clm_22CDDDACC93C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800322000094/0000078003-22-000094-index.htm.","url":"https://asof.is/claim/clm_22CDDDACC93C","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,612,351,809 shares","status":"superseded","assertable":true,"id":"clm_22CDDDACC93C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2022, filed 2022-08-10"}},{"date":"2022-10-02","until":"2023-04-02","published":"2023-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 22,638,000,000 United States dollar\", as of 2022-10-02 (until 2023-04-02). Claim clm_016037710298, https://asof.is/claim/clm_016037710298, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000115/0000078003-23-000115-index.htm.","url":"https://asof.is/claim/clm_016037710298","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"22,638,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_016037710298","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2023, filed 2023-11-08"}},{"date":"2022-10-02","until":"2023-04-02","published":"2022-11-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 8,608,000,000 United States dollar\", as of 2022-10-02 (until 2023-04-02). Claim clm_0A71910D2BF0, https://asof.is/claim/clm_0A71910D2BF0, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800322000101/0000078003-22-000101-index.htm.","url":"https://asof.is/claim/clm_0A71910D2BF0","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"8,608,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0A71910D2BF0","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2022, filed 2022-11-09"}},{"date":"2022-10-02","until":"2022-12-31","published":"2022-11-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 195,350,000,000 United States dollar\", as of 2022-10-02 (until 2022-12-31). Claim clm_6CD0D683E3D6, https://asof.is/claim/clm_6CD0D683E3D6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800322000101/0000078003-22-000101-index.htm.","url":"https://asof.is/claim/clm_6CD0D683E3D6","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"195,350,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6CD0D683E3D6","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2022, filed 2022-11-09"}},{"date":"2022-10-02","until":"2022-12-31","published":"2022-11-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 92,631,000,000 United States dollar\", as of 2022-10-02 (until 2022-12-31). Claim clm_7879485B76F5, https://asof.is/claim/clm_7879485B76F5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800322000101/0000078003-22-000101-index.htm.","url":"https://asof.is/claim/clm_7879485B76F5","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"92,631,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7879485B76F5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2022, filed 2022-11-09"}},{"date":"2022-10-02","until":"2022-12-31","published":"2022-11-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,298,000,000 United States dollar\", as of 2022-10-02 (until 2022-12-31). Claim clm_C60D5313CB4D, https://asof.is/claim/clm_C60D5313CB4D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800322000101/0000078003-22-000101-index.htm.","url":"https://asof.is/claim/clm_C60D5313CB4D","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,298,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_C60D5313CB4D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2022, filed 2022-11-09"}},{"date":"2022-11-04","until":"2023-02-21","published":"2022-11-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,613,314,537 shares\", as of 2022-11-04 (until 2023-02-21). Claim clm_9D2EE5E25C10, https://asof.is/claim/clm_9D2EE5E25C10, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800322000101/0000078003-22-000101-index.htm.","url":"https://asof.is/claim/clm_9D2EE5E25C10","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,613,314,537 shares","status":"superseded","assertable":true,"id":"clm_9D2EE5E25C10","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2022, filed 2022-11-09"}},{"date":"2022-12-31","until":"2023-04-02","published":"2023-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 197,205,000,000 United States dollar\", as of 2022-12-31 (until 2023-04-02). Claim clm_707918E5BC11, https://asof.is/claim/clm_707918E5BC11, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000024/0000078003-23-000024-index.htm.","url":"https://asof.is/claim/clm_707918E5BC11","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"197,205,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_707918E5BC11","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2022, filed 2023-02-23"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer revenue: 100,330,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_76057CE24462, https://asof.is/claim/clm_76057CE24462, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000024/0000078003-23-000024-index.htm.","url":"https://asof.is/claim/clm_76057CE24462","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"100,330,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_76057CE24462","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2022, filed 2023-02-23"}},{"date":"2022-12-31","until":"2023-12-31","published":"2023-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 31,372,000,000 United States dollar\", as of 2022-12-31 (until 2023-12-31). Claim clm_8A832B97B4FD, https://asof.is/claim/clm_8A832B97B4FD, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000024/0000078003-23-000024-index.htm.","url":"https://asof.is/claim/clm_8A832B97B4FD","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"31,372,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8A832B97B4FD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2022, filed 2023-02-23"}},{"date":"2022-12-31","until":"2023-04-02","published":"2023-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 95,661,000,000 United States dollar\", as of 2022-12-31 (until 2023-04-02). Claim clm_BD2455FA5B0F, https://asof.is/claim/clm_BD2455FA5B0F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000024/0000078003-23-000024-index.htm.","url":"https://asof.is/claim/clm_BD2455FA5B0F","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"95,661,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BD2455FA5B0F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2022, filed 2023-02-23"}},{"date":"2022-12-31","until":"2023-04-02","published":"2023-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 416,000,000 United States dollar\", as of 2022-12-31 (until 2023-04-02). Claim clm_ECCBC85FB453, https://asof.is/claim/clm_ECCBC85FB453, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000024/0000078003-23-000024-index.htm.","url":"https://asof.is/claim/clm_ECCBC85FB453","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"416,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ECCBC85FB453","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2022, filed 2023-02-23"}},{"date":"2023-02-21","until":"2023-05-05","published":"2023-02-23","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,619,074,621 shares\", as of 2023-02-21 (until 2023-05-05). Claim clm_347B7531EFEA, https://asof.is/claim/clm_347B7531EFEA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000024/0000078003-23-000024-index.htm.","url":"https://asof.is/claim/clm_347B7531EFEA","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,619,074,621 shares","status":"superseded","assertable":true,"id":"clm_347B7531EFEA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2022, filed 2023-02-23"}},{"date":"2023-04-02","until":"2023-07-02","published":"2023-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,166,000,000 United States dollar\", as of 2023-04-02 (until 2023-07-02). Claim clm_0EEAB3FF5071, https://asof.is/claim/clm_0EEAB3FF5071, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000162828023017196/0001628280-23-017196-index.htm.","url":"https://asof.is/claim/clm_0EEAB3FF5071","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,166,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0EEAB3FF5071","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2023, filed 2023-05-10"}},{"date":"2023-04-02","until":"2023-07-02","published":"2023-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 100,970,000,000 United States dollar\", as of 2023-04-02 (until 2023-07-02). Claim clm_1B7EEE491565, https://asof.is/claim/clm_1B7EEE491565, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000162828023017196/0001628280-23-017196-index.htm.","url":"https://asof.is/claim/clm_1B7EEE491565","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"100,970,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1B7EEE491565","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2023, filed 2023-05-10"}},{"date":"2023-04-02","until":"2023-07-02","published":"2023-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 18,282,000,000 United States dollar\", as of 2023-04-02 (until 2023-07-02). Claim clm_639F87C977AC, https://asof.is/claim/clm_639F87C977AC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000162828023017196/0001628280-23-017196-index.htm.","url":"https://asof.is/claim/clm_639F87C977AC","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"18,282,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_639F87C977AC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2023, filed 2023-05-10"}},{"date":"2023-04-02","until":"2023-07-02","published":"2023-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 195,617,000,000 United States dollar\", as of 2023-04-02 (until 2023-07-02). Claim clm_7A1E96DAC837, https://asof.is/claim/clm_7A1E96DAC837, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000162828023017196/0001628280-23-017196-index.htm.","url":"https://asof.is/claim/clm_7A1E96DAC837","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"195,617,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7A1E96DAC837","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2023, filed 2023-05-10"}},{"date":"2023-04-02","until":"2023-07-02","published":"2023-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 5,543,000,000 United States dollar\", as of 2023-04-02 (until 2023-07-02). Claim clm_ABFB86022BAD, https://asof.is/claim/clm_ABFB86022BAD, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000162828023017196/0001628280-23-017196-index.htm.","url":"https://asof.is/claim/clm_ABFB86022BAD","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"5,543,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_ABFB86022BAD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2023, filed 2023-05-10"}},{"date":"2023-05-05","until":"2023-08-04","published":"2023-05-10","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,645,307,020 shares\", as of 2023-05-05 (until 2023-08-04). Claim clm_E930D02B4072, https://asof.is/claim/clm_E930D02B4072, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000162828023017196/0001628280-23-017196-index.htm.","url":"https://asof.is/claim/clm_E930D02B4072","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,645,307,020 shares","status":"superseded","assertable":true,"id":"clm_E930D02B4072","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2023, filed 2023-05-10"}},{"date":"2023-07-02","until":"2023-10-01","published":"2023-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 12,734,000,000 United States dollar\", as of 2023-07-02 (until 2023-10-01). Claim clm_2B41EF883A6E, https://asof.is/claim/clm_2B41EF883A6E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000088/0000078003-23-000088-index.htm.","url":"https://asof.is/claim/clm_2B41EF883A6E","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"12,734,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2B41EF883A6E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2023, filed 2023-08-09"}},{"date":"2023-07-02","until":"2023-10-01","published":"2023-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 99,019,000,000 United States dollar\", as of 2023-07-02 (until 2023-10-01). Claim clm_86EDC9BD589A, https://asof.is/claim/clm_86EDC9BD589A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000088/0000078003-23-000088-index.htm.","url":"https://asof.is/claim/clm_86EDC9BD589A","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"99,019,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_86EDC9BD589A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2023, filed 2023-08-09"}},{"date":"2023-07-02","until":"2023-10-01","published":"2023-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 220,168,000,000 United States dollar\", as of 2023-07-02 (until 2023-10-01). Claim clm_A4E803452050, https://asof.is/claim/clm_A4E803452050, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000088/0000078003-23-000088-index.htm.","url":"https://asof.is/claim/clm_A4E803452050","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"220,168,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A4E803452050","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2023, filed 2023-08-09"}},{"date":"2023-07-02","until":"2023-10-01","published":"2023-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,327,000,000 United States dollar\", as of 2023-07-02 (until 2023-10-01). Claim clm_BE36346FE5EC, https://asof.is/claim/clm_BE36346FE5EC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000088/0000078003-23-000088-index.htm.","url":"https://asof.is/claim/clm_BE36346FE5EC","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,327,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BE36346FE5EC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2023, filed 2023-08-09"}},{"date":"2023-07-02","until":"2023-10-01","published":"2023-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,632,000,000 United States dollar\", as of 2023-07-02 (until 2023-10-01). Claim clm_F50B57CEE0C8, https://asof.is/claim/clm_F50B57CEE0C8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000088/0000078003-23-000088-index.htm.","url":"https://asof.is/claim/clm_F50B57CEE0C8","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,632,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F50B57CEE0C8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2023, filed 2023-08-09"}},{"date":"2023-08-04","until":"2023-11-03","published":"2023-08-09","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,645,959,570 shares\", as of 2023-08-04 (until 2023-11-03). Claim clm_9672FCCF2DBD, https://asof.is/claim/clm_9672FCCF2DBD, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000088/0000078003-23-000088-index.htm.","url":"https://asof.is/claim/clm_9672FCCF2DBD","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,645,959,570 shares","status":"superseded","assertable":true,"id":"clm_9672FCCF2DBD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2023, filed 2023-08-09"}},{"date":"2023-10-01","until":"2024-03-31","published":"2023-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: -2,382,000,000 United States dollar\", as of 2023-10-01 (until 2024-03-31). Claim clm_00135EC474FF, https://asof.is/claim/clm_00135EC474FF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000115/0000078003-23-000115-index.htm.","url":"https://asof.is/claim/clm_00135EC474FF","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"-2,382,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_00135EC474FF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2023, filed 2023-11-08"}},{"date":"2023-10-01","until":"2024-03-31","published":"2023-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 13,232,000,000 United States dollar\", as of 2023-10-01 (until 2024-03-31). Claim clm_32A8AAE2633D, https://asof.is/claim/clm_32A8AAE2633D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000115/0000078003-23-000115-index.htm.","url":"https://asof.is/claim/clm_32A8AAE2633D","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"13,232,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_32A8AAE2633D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2023, filed 2023-11-08"}},{"date":"2023-10-01","until":"2023-12-31","published":"2023-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 3,148,000,000 United States dollar\", as of 2023-10-01 (until 2023-12-31). Claim clm_6AE1E718957A, https://asof.is/claim/clm_6AE1E718957A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000115/0000078003-23-000115-index.htm.","url":"https://asof.is/claim/clm_6AE1E718957A","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"3,148,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6AE1E718957A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2023, filed 2023-11-08"}},{"date":"2023-10-01","until":"2023-12-31","published":"2023-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 96,934,000,000 United States dollar\", as of 2023-10-01 (until 2023-12-31). Claim clm_6D3607346B94, https://asof.is/claim/clm_6D3607346B94, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000115/0000078003-23-000115-index.htm.","url":"https://asof.is/claim/clm_6D3607346B94","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"96,934,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_6D3607346B94","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2023, filed 2023-11-08"}},{"date":"2023-10-01","until":"2023-12-31","published":"2023-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 215,021,000,000 United States dollar\", as of 2023-10-01 (until 2023-12-31). Claim clm_F1683296936F, https://asof.is/claim/clm_F1683296936F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000115/0000078003-23-000115-index.htm.","url":"https://asof.is/claim/clm_F1683296936F","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"215,021,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F1683296936F","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2023, filed 2023-11-08"}},{"date":"2023-11-03","until":"2024-02-15","published":"2023-11-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,646,413,292 shares\", as of 2023-11-03 (until 2024-02-15). Claim clm_ECD3729AEA0D, https://asof.is/claim/clm_ECD3729AEA0D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800323000115/0000078003-23-000115-index.htm.","url":"https://asof.is/claim/clm_ECD3729AEA0D","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,646,413,292 shares","status":"superseded","assertable":true,"id":"clm_ECD3729AEA0D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2023, filed 2023-11-08"}},{"date":"2023-12-31","until":"2024-03-31","published":"2024-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 2,853,000,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_77B4CFC0FCEC, https://asof.is/claim/clm_77B4CFC0FCEC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000039/0000078003-24-000039-index.htm.","url":"https://asof.is/claim/clm_77B4CFC0FCEC","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"2,853,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_77B4CFC0FCEC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2023, filed 2024-02-22"}},{"date":"2023-12-31","until":"2024-03-31","published":"2024-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 226,501,000,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_96987E07EFFB, https://asof.is/claim/clm_96987E07EFFB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000039/0000078003-24-000039-index.htm.","url":"https://asof.is/claim/clm_96987E07EFFB","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"226,501,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_96987E07EFFB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2023, filed 2024-02-22"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 2,119,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_BE5DA6BB4EA3, https://asof.is/claim/clm_BE5DA6BB4EA3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000039/0000078003-24-000039-index.htm.","url":"https://asof.is/claim/clm_BE5DA6BB4EA3","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"2,119,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BE5DA6BB4EA3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2023, filed 2024-02-22"}},{"date":"2023-12-31","until":"2024-12-31","published":"2024-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer revenue: 58,496,000,000 United States dollar\", as of 2023-12-31 (until 2024-12-31). Claim clm_E6A536D7125D, https://asof.is/claim/clm_E6A536D7125D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000039/0000078003-24-000039-index.htm.","url":"https://asof.is/claim/clm_E6A536D7125D","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"58,496,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_E6A536D7125D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2023, filed 2024-02-22"}},{"date":"2023-12-31","until":"2024-03-31","published":"2024-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 89,014,000,000 United States dollar\", as of 2023-12-31 (until 2024-03-31). Claim clm_F8EB8D7F466A, https://asof.is/claim/clm_F8EB8D7F466A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000039/0000078003-24-000039-index.htm.","url":"https://asof.is/claim/clm_F8EB8D7F466A","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"89,014,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_F8EB8D7F466A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2023, filed 2024-02-22"}},{"date":"2024-02-15","until":"2024-05-03","published":"2024-02-22","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,646,778,425 shares\", as of 2024-02-15 (until 2024-05-03). Claim clm_31BACD0D05FE, https://asof.is/claim/clm_31BACD0D05FE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000039/0000078003-24-000039-index.htm.","url":"https://asof.is/claim/clm_31BACD0D05FE","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,646,778,425 shares","status":"superseded","assertable":true,"id":"clm_31BACD0D05FE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2023, filed 2024-02-22"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 14,879,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_1956610004AC, https://asof.is/claim/clm_1956610004AC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000107/0000078003-24-000107-index.htm.","url":"https://asof.is/claim/clm_1956610004AC","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"14,879,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_1956610004AC","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2024, filed 2024-05-08"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 719,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_43D2163B4396, https://asof.is/claim/clm_43D2163B4396, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000107/0000078003-24-000107-index.htm.","url":"https://asof.is/claim/clm_43D2163B4396","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"719,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_43D2163B4396","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2024, filed 2024-05-08"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 221,095,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_4CE0593B01CD, https://asof.is/claim/clm_4CE0593B01CD, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000107/0000078003-24-000107-index.htm.","url":"https://asof.is/claim/clm_4CE0593B01CD","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"221,095,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4CE0593B01CD","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2024, filed 2024-05-08"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 92,282,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_AED99C6A7F37, https://asof.is/claim/clm_AED99C6A7F37, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000107/0000078003-24-000107-index.htm.","url":"https://asof.is/claim/clm_AED99C6A7F37","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"92,282,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_AED99C6A7F37","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2024, filed 2024-05-08"}},{"date":"2024-03-31","until":"2024-06-30","published":"2024-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 3,115,000,000 United States dollar\", as of 2024-03-31 (until 2024-06-30). Claim clm_B26D34B69468, https://asof.is/claim/clm_B26D34B69468, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000107/0000078003-24-000107-index.htm.","url":"https://asof.is/claim/clm_B26D34B69468","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"3,115,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B26D34B69468","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2024, filed 2024-05-08"}},{"date":"2024-05-03","until":"2024-07-31","published":"2024-05-08","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,666,592,898 shares\", as of 2024-05-03 (until 2024-07-31). Claim clm_815B3BB3A210, https://asof.is/claim/clm_815B3BB3A210, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000107/0000078003-24-000107-index.htm.","url":"https://asof.is/claim/clm_815B3BB3A210","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,666,592,898 shares","status":"superseded","assertable":true,"id":"clm_815B3BB3A210","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2024, filed 2024-05-08"}},{"date":"2024-06-30","until":"2024-09-29","published":"2024-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 41,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-29). Claim clm_195D8467B4BE, https://asof.is/claim/clm_195D8467B4BE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000166/0000078003-24-000166-index.htm.","url":"https://asof.is/claim/clm_195D8467B4BE","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"41,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_195D8467B4BE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2024, filed 2024-08-05"}},{"date":"2024-06-30","until":"2024-09-29","published":"2024-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 87,700,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-29). Claim clm_2DB055D564AE, https://asof.is/claim/clm_2DB055D564AE, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000166/0000078003-24-000166-index.htm.","url":"https://asof.is/claim/clm_2DB055D564AE","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"87,700,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_2DB055D564AE","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2024, filed 2024-08-05"}},{"date":"2024-06-30","until":"2024-09-29","published":"2024-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,052,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-29). Claim clm_7450D3EFB6A4, https://asof.is/claim/clm_7450D3EFB6A4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000166/0000078003-24-000166-index.htm.","url":"https://asof.is/claim/clm_7450D3EFB6A4","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,052,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7450D3EFB6A4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2024, filed 2024-08-05"}},{"date":"2024-06-30","until":"2024-09-29","published":"2024-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 216,193,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-29). Claim clm_A714E1EAAFF5, https://asof.is/claim/clm_A714E1EAAFF5, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000166/0000078003-24-000166-index.htm.","url":"https://asof.is/claim/clm_A714E1EAAFF5","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"216,193,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A714E1EAAFF5","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2024, filed 2024-08-05"}},{"date":"2024-06-30","until":"2024-09-29","published":"2024-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 13,283,000,000 United States dollar\", as of 2024-06-30 (until 2024-09-29). Claim clm_D9138859F83D, https://asof.is/claim/clm_D9138859F83D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000166/0000078003-24-000166-index.htm.","url":"https://asof.is/claim/clm_D9138859F83D","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"13,283,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_D9138859F83D","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2024, filed 2024-08-05"}},{"date":"2024-07-31","until":"2024-10-30","published":"2024-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,666,695,064 shares\", as of 2024-07-31 (until 2024-10-30). Claim clm_DA0681165988, https://asof.is/claim/clm_DA0681165988, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000166/0000078003-24-000166-index.htm.","url":"https://asof.is/claim/clm_DA0681165988","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,666,695,064 shares","status":"superseded","assertable":true,"id":"clm_DA0681165988","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2024, filed 2024-08-05"}},{"date":"2024-09-29","until":"2024-12-31","published":"2024-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 92,286,000,000 United States dollar\", as of 2024-09-29 (until 2024-12-31). Claim clm_0C71B8E54058, https://asof.is/claim/clm_0C71B8E54058, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000191/0000078003-24-000191-index.htm.","url":"https://asof.is/claim/clm_0C71B8E54058","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"92,286,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0C71B8E54058","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2024, filed 2024-11-04"}},{"date":"2024-09-29","until":"2024-12-31","published":"2024-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,092,000,000 United States dollar\", as of 2024-09-29 (until 2024-12-31). Claim clm_29C6E8E10D4B, https://asof.is/claim/clm_29C6E8E10D4B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000191/0000078003-24-000191-index.htm.","url":"https://asof.is/claim/clm_29C6E8E10D4B","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,092,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_29C6E8E10D4B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2024, filed 2024-11-04"}},{"date":"2024-09-29","until":"2025-03-30","published":"2024-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 17,702,000,000 United States dollar\", as of 2024-09-29 (until 2025-03-30). Claim clm_4E14C8BB5BD2, https://asof.is/claim/clm_4E14C8BB5BD2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000191/0000078003-24-000191-index.htm.","url":"https://asof.is/claim/clm_4E14C8BB5BD2","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"17,702,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_4E14C8BB5BD2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2024, filed 2024-11-04"}},{"date":"2024-09-29","until":"2024-12-31","published":"2024-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 219,476,000,000 United States dollar\", as of 2024-09-29 (until 2024-12-31). Claim clm_9A2C157E3B2C, https://asof.is/claim/clm_9A2C157E3B2C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000191/0000078003-24-000191-index.htm.","url":"https://asof.is/claim/clm_9A2C157E3B2C","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"219,476,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9A2C157E3B2C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2024, filed 2024-11-04"}},{"date":"2024-09-29","until":"2025-03-30","published":"2024-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 4,465,000,000 United States dollar\", as of 2024-09-29 (until 2025-03-30). Claim clm_A814E2CC5D7C, https://asof.is/claim/clm_A814E2CC5D7C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000191/0000078003-24-000191-index.htm.","url":"https://asof.is/claim/clm_A814E2CC5D7C","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"4,465,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A814E2CC5D7C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2024, filed 2024-11-04"}},{"date":"2024-10-30","until":"2025-02-20","published":"2024-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,666,990,035 shares\", as of 2024-10-30 (until 2025-02-20). Claim clm_953C1DCE94E7, https://asof.is/claim/clm_953C1DCE94E7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800324000191/0000078003-24-000191-index.htm.","url":"https://asof.is/claim/clm_953C1DCE94E7","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,666,990,035 shares","status":"superseded","assertable":true,"id":"clm_953C1DCE94E7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2024, filed 2024-11-04"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer revenue: 63,627,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_0D26120DBD16, https://asof.is/claim/clm_0D26120DBD16, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/0000078003-25-000054-index.htm.","url":"https://asof.is/claim/clm_0D26120DBD16","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"63,627,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0D26120DBD16","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2024, filed 2025-02-27"}},{"date":"2024-12-31","until":"2025-12-31","published":"2025-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 8,031,000,000 United States dollar\", as of 2024-12-31 (until 2025-12-31). Claim clm_9E891C94D652, https://asof.is/claim/clm_9E891C94D652, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/0000078003-25-000054-index.htm.","url":"https://asof.is/claim/clm_9E891C94D652","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"8,031,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_9E891C94D652","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2024, filed 2025-02-27"}},{"date":"2024-12-31","until":"2025-03-30","published":"2025-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 88,203,000,000 United States dollar\", as of 2024-12-31 (until 2025-03-30). Claim clm_B557B3FD5401, https://asof.is/claim/clm_B557B3FD5401, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/0000078003-25-000054-index.htm.","url":"https://asof.is/claim/clm_B557B3FD5401","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"88,203,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B557B3FD5401","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2024, filed 2025-02-27"}},{"date":"2024-12-31","until":"2025-03-30","published":"2025-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 213,396,000,000 United States dollar\", as of 2024-12-31 (until 2025-03-30). Claim clm_B6BEF1275567, https://asof.is/claim/clm_B6BEF1275567, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/0000078003-25-000054-index.htm.","url":"https://asof.is/claim/clm_B6BEF1275567","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"213,396,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B6BEF1275567","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2024, filed 2025-02-27"}},{"date":"2024-12-31","until":"2025-03-30","published":"2025-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,043,000,000 United States dollar\", as of 2024-12-31 (until 2025-03-30). Claim clm_BE556C30107A, https://asof.is/claim/clm_BE556C30107A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/0000078003-25-000054-index.htm.","url":"https://asof.is/claim/clm_BE556C30107A","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,043,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BE556C30107A","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2024, filed 2025-02-27"}},{"date":"2025-02-20","until":"2025-04-30","published":"2025-02-27","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,667,340,414 shares\", as of 2025-02-20 (until 2025-04-30). Claim clm_7F6190001A86, https://asof.is/claim/clm_7F6190001A86, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000054/0000078003-25-000054-index.htm.","url":"https://asof.is/claim/clm_7F6190001A86","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,667,340,414 shares","status":"superseded","assertable":true,"id":"clm_7F6190001A86","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2024, filed 2025-02-27"}},{"date":"2025-03-30","until":"2025-06-29","published":"2025-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 13,715,000,000 United States dollar\", as of 2025-03-30 (until 2025-06-29). Claim clm_3C91DD693306, https://asof.is/claim/clm_3C91DD693306, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000114/0000078003-25-000114-index.htm.","url":"https://asof.is/claim/clm_3C91DD693306","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"13,715,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_3C91DD693306","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2025, filed 2025-05-05"}},{"date":"2025-03-30","until":"2025-06-29","published":"2025-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 90,338,000,000 United States dollar\", as of 2025-03-30 (until 2025-06-29). Claim clm_459EB43571FA, https://asof.is/claim/clm_459EB43571FA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000114/0000078003-25-000114-index.htm.","url":"https://asof.is/claim/clm_459EB43571FA","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"90,338,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_459EB43571FA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2025, filed 2025-05-05"}},{"date":"2025-03-30","until":"2025-06-29","published":"2025-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,430,000,000 United States dollar\", as of 2025-03-30 (until 2025-06-29). Claim clm_45C7DD95C184, https://asof.is/claim/clm_45C7DD95C184, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000114/0000078003-25-000114-index.htm.","url":"https://asof.is/claim/clm_45C7DD95C184","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,430,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_45C7DD95C184","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2025, filed 2025-05-05"}},{"date":"2025-03-30","until":"2025-06-29","published":"2025-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 208,028,000,000 United States dollar\", as of 2025-03-30 (until 2025-06-29). Claim clm_8A616A5E1E47, https://asof.is/claim/clm_8A616A5E1E47, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000114/0000078003-25-000114-index.htm.","url":"https://asof.is/claim/clm_8A616A5E1E47","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"208,028,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8A616A5E1E47","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2025, filed 2025-05-05"}},{"date":"2025-03-30","until":"2025-06-29","published":"2025-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,967,000,000 United States dollar\", as of 2025-03-30 (until 2025-06-29). Claim clm_8A70F055C22B, https://asof.is/claim/clm_8A70F055C22B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000114/0000078003-25-000114-index.htm.","url":"https://asof.is/claim/clm_8A70F055C22B","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,967,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_8A70F055C22B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2025, filed 2025-05-05"}},{"date":"2025-04-30","until":"2025-07-30","published":"2025-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,685,365,587 shares\", as of 2025-04-30 (until 2025-07-30). Claim clm_37F113D82C0E, https://asof.is/claim/clm_37F113D82C0E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000114/0000078003-25-000114-index.htm.","url":"https://asof.is/claim/clm_37F113D82C0E","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,685,365,587 shares","status":"superseded","assertable":true,"id":"clm_37F113D82C0E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2025, filed 2025-05-05"}},{"date":"2025-06-29","until":"2025-09-28","published":"2025-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 14,653,000,000 United States dollar\", as of 2025-06-29 (until 2025-09-28). Claim clm_502A97F831BF, https://asof.is/claim/clm_502A97F831BF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000138/0000078003-25-000138-index.htm.","url":"https://asof.is/claim/clm_502A97F831BF","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"14,653,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_502A97F831BF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2025, filed 2025-08-05"}},{"date":"2025-06-29","until":"2025-09-28","published":"2025-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,910,000,000 United States dollar\", as of 2025-06-29 (until 2025-09-28). Claim clm_780D0923F526, https://asof.is/claim/clm_780D0923F526, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000138/0000078003-25-000138-index.htm.","url":"https://asof.is/claim/clm_780D0923F526","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,910,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_780D0923F526","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2025, filed 2025-08-05"}},{"date":"2025-06-29","until":"2025-09-28","published":"2025-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,638,000,000 United States dollar\", as of 2025-06-29 (until 2025-09-28). Claim clm_A443E97BB822, https://asof.is/claim/clm_A443E97BB822, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000138/0000078003-25-000138-index.htm.","url":"https://asof.is/claim/clm_A443E97BB822","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,638,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A443E97BB822","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2025, filed 2025-08-05"}},{"date":"2025-06-29","until":"2025-09-28","published":"2025-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 88,695,000,000 United States dollar\", as of 2025-06-29 (until 2025-09-28). Claim clm_A67CFCA124FF, https://asof.is/claim/clm_A67CFCA124FF, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000138/0000078003-25-000138-index.htm.","url":"https://asof.is/claim/clm_A67CFCA124FF","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"88,695,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_A67CFCA124FF","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2025, filed 2025-08-05"}},{"date":"2025-06-29","until":"2025-09-28","published":"2025-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 206,095,000,000 United States dollar\", as of 2025-06-29 (until 2025-09-28). Claim clm_BC91AD0A0FA7, https://asof.is/claim/clm_BC91AD0A0FA7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000138/0000078003-25-000138-index.htm.","url":"https://asof.is/claim/clm_BC91AD0A0FA7","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"206,095,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BC91AD0A0FA7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2025, filed 2025-08-05"}},{"date":"2025-07-30","until":"2025-10-29","published":"2025-08-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,685,550,500 shares\", as of 2025-07-30 (until 2025-10-29). Claim clm_556658F10CBB, https://asof.is/claim/clm_556658F10CBB, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000138/0000078003-25-000138-index.htm.","url":"https://asof.is/claim/clm_556658F10CBB","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,685,550,500 shares","status":"superseded","assertable":true,"id":"clm_556658F10CBB","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2025, filed 2025-08-05"}},{"date":"2025-09-28","until":"2026-03-29","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 16,654,000,000 United States dollar\", as of 2025-09-28 (until 2026-03-29). Claim clm_259CE7C5C459, https://asof.is/claim/clm_259CE7C5C459, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/0000078003-25-000150-index.htm.","url":"https://asof.is/claim/clm_259CE7C5C459","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"16,654,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_259CE7C5C459","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2025, filed 2025-11-04"}},{"date":"2025-09-28","until":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,343,000,000 United States dollar\", as of 2025-09-28 (until 2025-12-31). Claim clm_7F3FCDE33BD4, https://asof.is/claim/clm_7F3FCDE33BD4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/0000078003-25-000150-index.htm.","url":"https://asof.is/claim/clm_7F3FCDE33BD4","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,343,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7F3FCDE33BD4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2025, filed 2025-11-04"}},{"date":"2025-09-28","until":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 92,801,000,000 United States dollar\", as of 2025-09-28 (until 2025-12-31). Claim clm_84E5FD850428, https://asof.is/claim/clm_84E5FD850428, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/0000078003-25-000150-index.htm.","url":"https://asof.is/claim/clm_84E5FD850428","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"92,801,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_84E5FD850428","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2025, filed 2025-11-04"}},{"date":"2025-09-28","until":"2025-12-31","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 208,731,000,000 United States dollar\", as of 2025-09-28 (until 2025-12-31). Claim clm_92D82FE1E9CA, https://asof.is/claim/clm_92D82FE1E9CA, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/0000078003-25-000150-index.htm.","url":"https://asof.is/claim/clm_92D82FE1E9CA","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"208,731,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_92D82FE1E9CA","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2025, filed 2025-11-04"}},{"date":"2025-09-28","until":"2026-03-29","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 3,541,000,000 United States dollar\", as of 2025-09-28 (until 2026-03-29). Claim clm_FDB33475C290, https://asof.is/claim/clm_FDB33475C290, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/0000078003-25-000150-index.htm.","url":"https://asof.is/claim/clm_FDB33475C290","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"3,541,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_FDB33475C290","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2025, filed 2025-11-04"}},{"date":"2025-10-29","until":"2026-02-19","published":"2025-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,685,707,552 shares\", as of 2025-10-29 (until 2026-02-19). Claim clm_5BDDB8D74479, https://asof.is/claim/clm_5BDDB8D74479, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800325000150/0000078003-25-000150-index.htm.","url":"https://asof.is/claim/clm_5BDDB8D74479","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,685,707,552 shares","status":"superseded","assertable":true,"id":"clm_5BDDB8D74479","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2025, filed 2025-11-04"}},{"date":"2025-12-31","until":"2026-03-29","published":"2026-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 208,160,000,000 United States dollar\", as of 2025-12-31 (until 2026-03-29). Claim clm_220B65364A06, https://asof.is/claim/clm_220B65364A06, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/0000078003-26-000026-index.htm.","url":"https://asof.is/claim/clm_220B65364A06","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"208,160,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_220B65364A06","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-K FY2025, filed 2026-02-26"}},{"date":"2025-12-31","until":null,"published":"2026-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer revenue: 62,579,000,000 United States dollar\", as of 2025-12-31. Claim clm_55A653F47AF3, https://asof.is/claim/clm_55A653F47AF3, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/0000078003-26-000026-index.htm.","url":"https://asof.is/claim/clm_55A653F47AF3","accessed":"2026-11-10"},"kind":"money","predicate":"revenue","value":"62,579,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_55A653F47AF3","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2025, filed 2026-02-26"}},{"date":"2025-12-31","until":"2026-03-29","published":"2026-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,142,000,000 United States dollar\", as of 2025-12-31 (until 2026-03-29). Claim clm_7D4C9A5A57B2, https://asof.is/claim/clm_7D4C9A5A57B2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/0000078003-26-000026-index.htm.","url":"https://asof.is/claim/clm_7D4C9A5A57B2","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,142,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7D4C9A5A57B2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-K FY2025, filed 2026-02-26"}},{"date":"2025-12-31","until":"2026-03-29","published":"2026-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 86,476,000,000 United States dollar\", as of 2025-12-31 (until 2026-03-29). Claim clm_7F8BD7A5E4E8, https://asof.is/claim/clm_7F8BD7A5E4E8, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/0000078003-26-000026-index.htm.","url":"https://asof.is/claim/clm_7F8BD7A5E4E8","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"86,476,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_7F8BD7A5E4E8","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-K FY2025, filed 2026-02-26"}},{"date":"2025-12-31","until":null,"published":"2026-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer net income: 7,771,000,000 United States dollar\", as of 2025-12-31. Claim clm_B68A9D81D6E4, https://asof.is/claim/clm_B68A9D81D6E4, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/0000078003-26-000026-index.htm.","url":"https://asof.is/claim/clm_B68A9D81D6E4","accessed":"2026-11-10"},"kind":"money","predicate":"net_income","value":"7,771,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_B68A9D81D6E4","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-26"}},{"date":"2026-02-19","until":"2026-04-29","published":"2026-02-26","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,686,267,431 shares\", as of 2026-02-19 (until 2026-04-29). Claim clm_51DCE9CF5E2B, https://asof.is/claim/clm_51DCE9CF5E2B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000026/0000078003-26-000026-index.htm.","url":"https://asof.is/claim/clm_51DCE9CF5E2B","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,686,267,431 shares","status":"superseded","assertable":true,"id":"clm_51DCE9CF5E2B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-K FY2025, filed 2026-02-26"}},{"date":"2026-03-29","until":"2026-06-28","published":"2026-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 14,451,000,000 United States dollar\", as of 2026-03-29 (until 2026-06-28). Claim clm_04BC67D14071, https://asof.is/claim/clm_04BC67D14071, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000054/0000078003-26-000054-index.htm.","url":"https://asof.is/claim/clm_04BC67D14071","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"14,451,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_04BC67D14071","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q1 FY2026, filed 2026-05-05"}},{"date":"2026-03-29","until":"2026-06-28","published":"2026-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 207,618,000,000 United States dollar\", as of 2026-03-29 (until 2026-06-28). Claim clm_0F454E788453, https://asof.is/claim/clm_0F454E788453, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000054/0000078003-26-000054-index.htm.","url":"https://asof.is/claim/clm_0F454E788453","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"207,618,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0F454E788453","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q1 FY2026, filed 2026-05-05"}},{"date":"2026-03-29","until":"2026-06-28","published":"2026-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 2,687,000,000 United States dollar\", as of 2026-03-29 (until 2026-06-28). Claim clm_53B07B940F0E, https://asof.is/claim/clm_53B07B940F0E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000054/0000078003-26-000054-index.htm.","url":"https://asof.is/claim/clm_53B07B940F0E","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"2,687,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_53B07B940F0E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q1 FY2026, filed 2026-05-05"}},{"date":"2026-03-29","until":"2026-06-28","published":"2026-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,703,000,000 United States dollar\", as of 2026-03-29 (until 2026-06-28). Claim clm_B30F323EDCA7, https://asof.is/claim/clm_B30F323EDCA7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000054/0000078003-26-000054-index.htm.","url":"https://asof.is/claim/clm_B30F323EDCA7","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,703,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_B30F323EDCA7","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q1 FY2026, filed 2026-05-05"}},{"date":"2026-03-29","until":"2026-06-28","published":"2026-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 90,101,000,000 United States dollar\", as of 2026-03-29 (until 2026-06-28). Claim clm_BC20BA361653, https://asof.is/claim/clm_BC20BA361653, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000054/0000078003-26-000054-index.htm.","url":"https://asof.is/claim/clm_BC20BA361653","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"90,101,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_BC20BA361653","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q1 FY2026, filed 2026-05-05"}},{"date":"2026-04-29","until":"2026-07-29","published":"2026-05-05","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,699,444,169 shares\", as of 2026-04-29 (until 2026-07-29). Claim clm_33249464D328, https://asof.is/claim/clm_33249464D328, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000054/0000078003-26-000054-index.htm.","url":"https://asof.is/claim/clm_33249464D328","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,699,444,169 shares","status":"superseded","assertable":true,"id":"clm_33249464D328","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q1 FY2026, filed 2026-05-05"}},{"date":"2026-06-28","until":"2026-09-27","published":"2026-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 85,190,000,000 United States dollar\", as of 2026-06-28 (until 2026-09-27). Claim clm_0E339552F309, https://asof.is/claim/clm_0E339552F309, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/0000078003-26-000095-index.htm.","url":"https://asof.is/claim/clm_0E339552F309","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"85,190,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_0E339552F309","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q2 FY2026, filed 2026-08-04"}},{"date":"2026-06-28","until":"2026-09-27","published":"2026-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 15,034,000,000 United States dollar\", as of 2026-06-28 (until 2026-09-27). Claim clm_565D11071768, https://asof.is/claim/clm_565D11071768, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/0000078003-26-000095-index.htm.","url":"https://asof.is/claim/clm_565D11071768","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"15,034,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_565D11071768","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q2 FY2026, filed 2026-08-04"}},{"date":"2026-06-28","until":"2026-09-27","published":"2026-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 976,000,000 United States dollar\", as of 2026-06-28 (until 2026-09-27). Claim clm_DD199C8B2D4B, https://asof.is/claim/clm_DD199C8B2D4B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/0000078003-26-000095-index.htm.","url":"https://asof.is/claim/clm_DD199C8B2D4B","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"976,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_DD199C8B2D4B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q2 FY2026, filed 2026-08-04"}},{"date":"2026-06-28","until":"2026-09-27","published":"2026-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: -248,000,000 United States dollar\", as of 2026-06-28 (until 2026-09-27). Claim clm_EE2E6677E705, https://asof.is/claim/clm_EE2E6677E705, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/0000078003-26-000095-index.htm.","url":"https://asof.is/claim/clm_EE2E6677E705","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"-248,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EE2E6677E705","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q2 FY2026, filed 2026-08-04"}},{"date":"2026-06-28","until":"2026-09-27","published":"2026-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 201,131,000,000 United States dollar\", as of 2026-06-28 (until 2026-09-27). Claim clm_EFF5D8F57EB2, https://asof.is/claim/clm_EFF5D8F57EB2, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/0000078003-26-000095-index.htm.","url":"https://asof.is/claim/clm_EFF5D8F57EB2","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"201,131,000,000 United States dollar","status":"superseded","assertable":true,"id":"clm_EFF5D8F57EB2","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q2 FY2026, filed 2026-08-04"}},{"date":"2026-07-29","until":"2026-10-28","published":"2026-08-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,699,673,589 shares\", as of 2026-07-29 (until 2026-10-28). Claim clm_E03E2668E863, https://asof.is/claim/clm_E03E2668E863, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/0000078003-26-000095-index.htm.","url":"https://asof.is/claim/clm_E03E2668E863","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,699,673,589 shares","status":"superseded","assertable":true,"id":"clm_E03E2668E863","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q2 FY2026, filed 2026-08-04"}},{"date":"2026-09-27","until":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer cash and equivalents: 1,824,000,000 United States dollar\", as of 2026-09-27. Claim clm_23E72D4D980E, https://asof.is/claim/clm_23E72D4D980E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm.","url":"https://asof.is/claim/clm_23E72D4D980E","accessed":"2026-11-10"},"kind":"money","predicate":"cash_and_equivalents","value":"1,824,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_23E72D4D980E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2026, filed 2026-11-03"}},{"date":"2026-09-27","until":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly net income: 3,242,000,000 United States dollar\", as of 2026-09-27. Claim clm_7B5F356BDB2E, https://asof.is/claim/clm_7B5F356BDB2E, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm.","url":"https://asof.is/claim/clm_7B5F356BDB2E","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_net_income","value":"3,242,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_7B5F356BDB2E","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-03"}},{"date":"2026-09-27","until":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total equity: 89,001,000,000 United States dollar\", as of 2026-09-27. Claim clm_84ED4CDADE9C, https://asof.is/claim/clm_84ED4CDADE9C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm.","url":"https://asof.is/claim/clm_84ED4CDADE9C","accessed":"2026-11-10"},"kind":"money","predicate":"total_equity","value":"89,001,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_84ED4CDADE9C","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-11-03"}},{"date":"2026-09-27","until":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer total assets: 204,544,000,000 United States dollar\", as of 2026-09-27. Claim clm_E3BBF3297E77, https://asof.is/claim/clm_E3BBF3297E77, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm.","url":"https://asof.is/claim/clm_E3BBF3297E77","accessed":"2026-11-10"},"kind":"money","predicate":"total_assets","value":"204,544,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_E3BBF3297E77","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-11-03"}},{"date":"2026-09-27","until":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer quarterly revenue: 16,583,000,000 United States dollar\", as of 2026-09-27. Claim clm_F01F5C40574B, https://asof.is/claim/clm_F01F5C40574B, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm.","url":"https://asof.is/claim/clm_F01F5C40574B","accessed":"2026-11-10"},"kind":"money","predicate":"quarterly_revenue","value":"16,583,000,000 United States dollar","status":"valid","assertable":true,"id":"clm_F01F5C40574B","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2026, filed 2026-11-03"}},{"date":"2026-10-28","until":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Pfizer shares outstanding: 5,699,853,733 shares\", as of 2026-10-28. Claim clm_7F37B9735E29, https://asof.is/claim/clm_7F37B9735E29, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/0000078003-26-000127-index.htm.","url":"https://asof.is/claim/clm_7F37B9735E29","accessed":"2026-11-10"},"kind":"money","predicate":"shares_outstanding","value":"5,699,853,733 shares","status":"valid","assertable":true,"id":"clm_7F37B9735E29","evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2026, filed 2026-11-03"}}],"complete":true,"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}